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The radioisotope zirconium-89 has attracted attention in recent years as a candidate for clinical 
use in positron emission tomography (PET), due to its favourable properties. Zirconium-89 has a 
long half-life of 78.4 hours, rendering it suitable for use in conjugation to monoclonal antibodies 
(mAB), therefore giving potential applications in personalised medicines. It also has favourable 
emission characteristics, such as low energy positron emissions. Furthermore, it can be produced 
at low cost. These factors combine to support zirconium-89 as a cheap and high-resolution 
radioisotope for PET imaging. The most widely used chelator of zirconium-89, desferrioxamine-
B (DFO), forms an insufficiently stable complex with zirconium-89 and undergoes some 
demetallation in vivo, leading to ablation of zirconium-89 to bone tissues. While recent efforts 
have focussed on developing novel chelators with more stable properties, 89Zr-DFO is the only 
complex which has been examined in a clinical setting, and novel zirconium chelators have 
required either difficult synthetic procedures or are insufficiently soluble. It is hypothesised that 
the ideal chelator for zirconium-89 will: bind via hydroxamate groups in an octadentate manner; 
be bifunctional; and be simple to synthesise. The novel chelators 8 and 10 were designed based 
on these criteria and to examine the feasibility of a zirconium-89 chelator incorporating α-amino 
acids. 
 
Synthesis of both compounds was attempted via a modular solution-phase peptide synthesis. 
The molecular subunits 4a and 4b were synthesised with overall yields of 21% and 48% 
respectively. However, during the latter stages of the synthesis intramolecular degradation of 
compounds 7 and 8 resulted in the formation of an alternative product: compound 8.1. Analytical 
evidence obtained through 1HNMR and HRMS suggested this occurred by a mechanism akin to 
aspartimide formation, as seen in solid-phase peptide synthesis. To examine this hypothesis, an 
alternative chelator 14 was designed, incorporating β-alanine in place of glycine. This compound 




was successfully synthesised via solid-phase peptide synthesis and identified with HRMS and 
1HNMR.  
 
As the monohydroxamate compound 8.1 was isolated as a pure product, it was of interest to 
assess its binding affinity for the radiometals zirconium-89 and gallium-68. The chelator was 
compared to DFO and subject to challenge assays to assess resistance to competitive metal ions, 
transchelation by EDTA, and non-specific protein binding. While it was evident that compound 
8.1 was inferior to DFO as a chelator of zirconium-89 under all conditions, it did display 
significantly increased stability than previously reported for monohydroxamate chelators. 
However, both compound 8.1 and DFO displayed low stability when complexed with gallium-68. 
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ACN: acetonitrile; AcOH: acetic acid; Boc: tert-butoxycarbonyl protecting group; Boc: tert-
Butyloxycarbonyl; BSA: bovine serum albumin; CAM: cerium ammonium molybdateDCM: 
dichloromethane; DIPEA: N-N-Diisopropylethylamine; DMF: N-N-dimethylformamide; EDTA: 
ethylenediaminetetraacetic acid; EtOAc: ethyl acetate; Fmoc: fluorenylmethyloxycarbonyl 
protecting group; HATU: 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-
oxid hexafluorophosphate; HPLC: High Performance Liquid Chromatography; HRMS: High 
Resolution Mass Spectrometry; IPA: Isopropyl alcohol; LRMS: Low Resolution Mass 
Spectrometry; MeOH: methanol; NMR: Nuclear Magnetic Resonance; OBn: Benzyl ether; PBS: 
Phosphate buffered saline; TFA: trifluoroacetic acid; THF: tetrahydrofuran. 
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1 New approaches to Positron Emission Tomography: 89Zr and 68Ga 
1.1 Background: Modern Approaches to the Detection of Cancer 
The treatment of cancer is one of the predominant medical issues of the modern day. In 2017, an 
estimated 134,174 cases of cancer were diagnosed, and an estimated 47,753 deaths were 
recorded as being a result of cancer in Australia. This comprised 19% of the total disease burden 
in Australia and cost upward of $4.25b.1 The risk of developing cancer increases substantially 
with increasing age and considering Australia’s aging national population, this burden of disease 
is only likely to increase. Cancer Australia has collected data pertaining to the diagnosis of the 
top 5 most common variants of cancer in Australia, with these being breast cancer, colorectal 
cancer, lung cancer, prostate cancer and malignant melanoma.2 Of these, the majority of cases 
of melanoma, breast cancer and prostate cancer were diagnosed during the early stages of 
cancer – at stage 1, indicating no metastasis; or stage 2, indicating limited metastasis into 
surrounding tissue.3 These cancer types had 5-year relative survival rates amongst the highest 
at 88%, 90% and 95% respectively.1 Colorectal cancer was diagnosed at stages 1 and 2 only 
slightly more than at stages 3 and 4 (indicating greater metastasis of tumours), and had a lower 
5-year survival rate of around 69%. Lung cancer was most commonly diagnosed at stage 4, and 
had one of the poorest 5-year prognoses of any cancer at 14% for males and 19% for females, 
indicating that the swift detection of cancers is crucial in providing effective and suitable treatment 
for the disease.1-2 While early detection is reliant on a diverse range of factors, the accessibility 
of resources for detection is of utmost importance: people living more remotely are not more likely 
to develop cancer than those in cities, but they are more likely to die as a result.1 Therefore, the 
availability of robust, reliable and easily-accessible detection methods is crucial for reducing 
mortality. 
 




Advancing knowledge of the mechanisms of tumour proliferation has led to changes in treatment 
methods. While DNA alkylating agents such as cis-platin are still in wide use,4 newer treatments 
are intended to target tumours with ever-increasing specificity. The targeting of cancer treatment 
carries several advantages: firstly, tumours which are resistant to traditional means of treatment 
can be better controlled; and secondly, damage to surrounding, healthy tissue is minimised while 
damage to tumorous tissue is maximised. Central to targeted therapy is the discovery of genetic 
or biological differences between tumour cells and healthy cells.5 Genetic differences can 
manifest in the over- or under-expression of proteins by tumourous cells, which allows more 
specific targeting of these tumours. Such proteins are known as biomarkers; some examples 
include the prostate-specific membrane antigen, which is highly expressed in prostate cancers,6 
and human epidermal growth factor receptor 2, highly expressed in some breast cancers.7 
Membrane-expressed biomarkers are of particular interest, as they can be targeted and inhibited 
with exogenous ligands. Inhibitors of these biomarkers can also be used to detect the extent and 
severity of cancers through medical imaging. 
 
The imaging methods of positron emission tomography (PET) and single photon emission 
computed tomography (SPECT) are regularly used for these purposes. Both methods require the 
injection of a radioisotope, known as a radiotracer. This radiotracer is intended to preferentially 
localise within tumours, the location and size of which can then be elucidated by the detection of 
radioactive emissions from the body. Naturally, in PET, a positron-emitting radioisotope is injected 
into the subject, while SPECT uses gamma-emitters. After emission, a positron collides with an 
electron and is annihilated, causing the generation of two identical photons with 511 kEV energy, 
which subsequently travel in opposite directions.8-9 The subject is surrounded by a photon sensor; 
this sensor will detect the incident photons and calculate their single point of origin. The 
calculations based on the measurement of hundreds of thousands of said emissions can be used 
to generate an image of the subject. The resolution of PET sensors, and therefore the images, is 




affected by several factors. Firstly, the energy of the positron affects the distance it travels before 
it is annihilated, which affects the accuracy of images. Similarly, residual kinetic motion at 
annihilation (Fermi motion, or translational motion) causes the angle between the photons to 
deviate from the original angle of 180°.10 Lastly, the specificity with which the radionuclide is 
localised affects image resolution; greater tumour-to-background ratios result in clearer images. 
The effect of Fermi motion is largely affected by the diameter of the detector, while the energy of 
the positron is inherent to the decay pathway of specific radionuclides.10 Radionuclide localisation 
however is dependent on the method of targeting. Even though PET is generally far more 
expensive than SPECT, the resolution obtained using the former is significantly better,8 and during 
PET the number of emissions in each location can be quantified, which is advantageous for 
assessing in vivo targeting of the radionuclide.11  
 
A variety of positron-emitters are utilised in PET, including carbon-11, nitrogen-13, oxygen-15, 
and fluorine-18. Less commonly, metals such as gallium-68 or copper-64 are used.8 The 
advantage of the above non-metallic radioisotopes is their ease of incorporation into biological 
molecules such as glucose (fluorine-18 is incorporated as 2-fluoro-2-deoxy-D-glucose, or FDG), 
as the increased energy demands of rapidly growing cancer cells ensure radiolabelled glucose 
will accumulate more rapidly in tumours than healthy cells.8 Alternatively, metallic radioisotopes 
require chelation to be transported into cells. This does, however, present the opportunity to target 
the radionuclide more specifically to cancer cells and lower background signals.  
  
With the exception of copper-64 (t1/2 = 12 h), each of the aforementioned radionuclides has quite 
a short half-life – 2 minutes for oxygen-15, 10 minutes for nitrogen-13, 20 minutes for carbon-11, 
68 minutes for gallium-68, and 110 minutes for fluorine-18. These short half-lives make urgency 
paramount in the use of these radioisotopes; they must be produced on the day of use, and the 
chemical reaction to incorporate them into some biologically relevant molecule must happen 




rapidly. In order to produce high-resolution images, the further processes of transportation, 
injection, and imaging must occur within a limited time. The setup of local cyclotrons or generators 
to reduce transport time can reduce the losses associated with short-lived radioisotopes, but the 
capital investment required to purchase and maintain a cyclotron is substantial. But there is a 
more pressing issue with the use of radioisotopes with short half-lives: a lack of specificity. As 
was previously mentioned, these radioisotopes are incorporated into biologically relevant 
molecules, such as glucose or water. These molecules are ubiquitous in living systems, and while 
tumours accumulate them at a greater rate than healthy tissue, they also readily incorporate into 
healthy tissues. This leads to increased background signals and causes lower image resolution.8  
 
Another clinically proven approach to cancer detection and treatment is the use of monoclonal 
antibodies, or mAB. mAB are large proteins with highly specific cellular targets, a feature which 
can prove beneficial to both detection and treatment by lowering background noise and increasing 
radiochemical delivery.11 In medical imaging, the use of mAB results in higher resolution images 
due to greater accumulation of the biomarker in cancerous tissue; in treatment, it should result in 
less collateral damage to healthy tissue. A further benefit is greater consistency between 
diagnostics and therapy. Such an incorporated approach to medicine is known as theranostics, a 
portmanteau of therapeutic and diagnostic.12 Targeted treatment can also aid the staging and 
identification of cancer subtypes; for instance, imaging using the HER2 inhibitor trastuzumab as 
a vector will not only indicate the extent of the tumour, but will also indicate whether a suspected 
cancer is susceptible to treatment through that same pathway, permitting greater personalisation 
of treatment. The attachment of a radioisotope to mAB is known as conjugation, which can occur 
via substitution for non-metals or chelation for metals, as seen in Figure 1. 








Figure 1: Diagram of a monoclonal antibody (mAB, black) with a conjugated radioisotope (yellow) 
connected by a linker (red).7 
This approach, however, requires a departure from the use of short-lived isotopes. mAB have a 
lengthy period of circulation after injection of around 2-4 days which renders them unsuitable for 
use with short-lived radioisotopes such as gallium-68 or fluorine-18.13 Even copper-64, with a 
half-life of 12 hours, is not ideal for this purpose. The use of alternative positron emitters with 
longer half-lives could therefore reduce waste during production and transportation and improve 
both resolution and the cost of PET procedures. Iodine-124 has been studied in this context due 
to its lengthy half-life of 4.18 days; however 124I-mAB systems are vulnerable to dehalogenation 
in vivo, causing retention of iodine-124 in the blood.14 Another positron emitter, zirconium-89, has 
been raised as a potential candidate for imaging procedures.  





Zirconium-89 is a positron-emitting, neutron-deficient isotope of zirconium, with a half-life of 3.3 
days.15 Zirconium-89 decays firstly into the metastable 89mY by positron emission (22.7%) and 
electron capture (77.3%),15 with the positron emission occurring at a relatively low average energy 
of 395 keV, and a maximum of 897 keV (Figure 2).7 The annihilation of this positron results in the 
emission of two opposing gamma rays with 511 keV of energy.15 The metastable 89mY further 
decays by a single gamma emission of 909 keV into stable yttrium-89. The gap between the 511 
keV photon and the 909 keV gamma ray has little to no spectral overlap, giving two discrete peaks 





Figure 2: Decay pathway of zirconium-89 to the stable 89Y via the metastable 89mY.16 
There is thus potential for zirconium-89 to carve out a therapeutic niche. The most attractive 
attribute of zirconium-89 is its extended half-life, which is well suited to conjugation to monoclonal 
antibodies, as these require a circulation time of approximately 2 - 4 days to facilitate sufficient 
uptake into cells for high-resolution imaging to occur.15 As stated previously, the use of 
monoclonal antibodies as a targeting mechanism improves the resolution of images compared to 
biologically ubiquitous molecules such as glucose. It further provides a more accurate model for 
antibody-based radiotherapy, which is becoming increasingly more common; a number of 
monoclonal antibody-based radiotherapies utilising long-lived radionuclides such as lutetium-177 
(half-life 6.7 days) to treat late-stage metastatic tumours have been successful in clinical trials.17 
Such a system benefits from an antibody-based method of imaging as this ensures consistency 
between imaging and treatment. Furthermore, the low average energy of the positron emitted by 
89Zr (t1/2 = 78.4 h) 
EC (77.0%) 
β+-decay (22.6%) 
 γ-decay (909 kEV, 99.0%)   
89mY (t1/2 = 23.9 fs) 
89Y 




zirconium-89 means the translational energy of the isotope after annihilation is low, further 
increasing the resolution of the images.16, 18 To this end, there has been some interest in 
zirconium-89 since the 1980s.19 
 
The standard production of high-purity zirconium-89 for therapeutic use was first reported by 
Meijs et al. in 1994,20 and developed further by Holland et al. in 2009.16 Yttrium-89 foil, naturally 
abundant as a single isotope, is placed into a shuttle and bombarded by a proton beam, 
converting it to zirconium-89 by the 89Y(p,n)89Zr transmutation reaction; controlling the energy of 
this bombardment is crucial so as not to promote the formation of zirconium-88. The threshold for 
formation of zirconium-89 occurs at 4.59 MeV, and the maximum average cross-section occurs 
at 13.80 MeV; the threshold for production of zirconium-88 is 13.30 MeV, suggesting the ideal 
proton energy is ~13 MeV.16 Following bombardment, the target is cooled while the metastable 
89mZr decays before dissolution of the foil in 6M hydrochloric acid. To separate zirconium-89 from 
impurities (particularly yttrium), the acidic solution is passed through a hydroxamate resin, which 
preferentially binds zirconium over yttrium. Washing this resin with hydrochloric acid removes the 
yttrium, after which zirconium-89 can be liberated from the resin by transchelation with 1M oxalic 
acid. This method yields zirconium-89 at a high radiochemical yield (>99.9%) as zirconium 
oxalate.16 Oxalic acid is highly toxic and therefore must be removed before any 
radiopharmaceutical production; this is achieved typically by elution through an anion exchange 
resin flushed with water, and subsequent washing of the resin with 1M HCl will yield 89ZrCl4.16 
Recent work has suggested that the published oxalic acid concentration can be further reduced 
without compromising the yield of zirconium-89.21 The automated production of radiopure 
zirconium-89 was published by Lin et al. which improves safety and consistency of production.22  
 
As this production method occurs with a relatively low-energy proton beam, it is possible to 
produce zirconium-89 with only a small medical cyclotron, reducing the costs of production.16 The 




advantages of zirconium-89-based imaging are therefore numerous compared to other long-lived 
radioisotopes: it can be produced relatively cheaply; it has a longer half-life than copper-64; and 
it has the potential to produce high-resolution images through precise targeting and its low-energy 
positron emissions. However, there are several challenges to overcome preceding its use in PET. 
The abundance of gamma radiation is of some concern; as previously mentioned, the decay of 
zirconium-89 to yttrium-89 occurs almost entirely by the emission of a 909keV gamma ray. This 
is a high energy emission which has a half-value of 10mm in lead and necessitates greater 
shielding than other isotopes, and could feasibly lead to mutation in vivo.7 Furthermore, the 
behaviour of free zirconium-89 ions in vivo means that highly stable chelation is necessary for its 
use in radiopharmaceuticals; this will be addressed below. 
 
Zirconium is a group IV metal which primarily exists in the Zr4+ form in solution, which has an ionic 
radius of 0.84 Å.18 This ion is reduced at -1.4 – 1.5 V, which exceeds the reduction potential 
present in biological systems.11 Zr4+ is a ‘hard’ Lewis acid which forms stable bonds with anionic 
oxygen or nitrogen donors, coordinating up to 8 ligands.  
 
Figure 3: X-ray crystallographic structure of zirconium(N-methyl acetohydroxamic acid)4 elucidated by 
Guérard et al.23The central zirconium ion (green) is coordinated by 4 hydroxamic acid subunits via the 
oxygen anions (red). 




Guerard et al. have reported both computational and crystallographic structures for Zr4+ 
complexed to four free hydroxamic acid units (Figure 3). The average bond lengths were found 
to differ between the two structures: average bond lengths of 2.204 Å and 2.183 Å for the Zr-O-
C and Zr-O-N bonds respectively were determined in the X-ray structure; meanwhile the 
calculated structure showed more disparate bond lengths of 2.324 Å and 2.199 Å respectively.23 
The difference between the two was rationalised as the existence of a second conformer, as the 
C-O and N-O groups are able to exchange positions. This study provides some insight into the 
necessary size and organisation of chelators intended for zirconium.  
 
While zirconium is present in many animal tissues naturally in low quantities, little is known about 
the biological effects at these quantities.24 Clearance of zirconium from the body greatly depends 
on the complex involved; while some complexes are rapidly cleared by the renal or hepatobiliary 
systems, some zirconium salts will precipitate and accumulate in the liver or spleen.18 Free Zr4+ 
ions show a tendency to migrate to calcified tissue in the bones in vivo, which is problematic in 
the clinical use of zirconium-89; the incorporation of a long-lasting, gamma-emitting radioisotope 
into radiosensitive tissue adjoining the bone marrow could prove dangerous. Therefore, the use 
of chelators which form stable complexes at very low concentrations is paramount.  
  




1.3 Chelation of zirconium-89 
1.3.1 Desferrioxamine-B 
The most widely studied and used chelator of zirconium-89 is presently the natural product 
desferrioxamine-B, also known as deferoxamine, desferal or DFO. DFO is a natural product that 
was first isolated from Streptomyces pilosus in the late 1950s,25 with its structure elucidated in 
1962 (Figure 4).26 A succession of 3 hydroxamate groups are separated by a peptide-like 
backbone, providing 6 oxygen atoms for chelation to a donor. DFO is a type of natural product 
known as a “siderophore”, classified as such due to its high affinity for Fe3+ compared to Fe2+.26 
It is thought that microorganisms utilise DFO to shuttle the largely insoluble Fe(III) into cells in 
oxygen-rich environments where this state predominates. While DFO also displays strong affinity 
for Al3+ (Kf = 21.4), this is significantly lower than that for Fe3+ (Kf = 30.6).26  
 
Figure 4: Desferrioxamine-B 
 
 
Figure 5: Mesomerisation of the hydroxamate group.26 
Hydroxamate groups have two resonance contributors (Figure 5), notably one in which the 
carbonyl oxygen becomes negatively charged, facilitating binding to donor atoms.26 At neutral pH 
values, the dissociation of Fe3+ from DFO is extremely slow. As the redox potential of NADH 
exceeds that of hydroxamate-based chelators, the release of Fe(III) from DFO is suspected to 
generally proceed by reduction to Fe(II), which forms a substantially less stable ligand-donor 
complex with DFO (Figure 6).26 
 





Figure 6: Desferrioxamine-B complexed with Fe(III) via hexadentate coordination.18 
While another category of siderophores – the catecholates - have greater affinity for Fe(III), 
hydroxamate-based siderophores have a greater stability at lower pH than the catecholates.26 
The complexation of a catecholate to a donor requires the displacement of 6 protons, compared 
to 3 protons for the hydroxamate, increasing the influence of pH on catecholates.26 This stability 
also renders natural hydroxamate-based siderophores more useful clinically.26 Based on its 
particular affinity for Fe(III), DFO has been approved as a drug for the treatment of acute iron 
toxicity, marketed as Desferal.15 Enterobactin (Figure 7), the most potent natural catecholate 
siderophore, is unsuitable for in vivo use due to rapid hydrolysis at physiological pH; however, 
more stable derivatives of it are widespread in clinical use in conjunction with gallium-68.27  
 
Figure 7: Enterobactin, a catecholate siderophore isolated from Salmonella typhimurium and the 
siderophore with the greatest known affinity for Fe(III).26 
DFO has also been studied extensively as a chelator for a variety of radiopharmaceuticals, 
including gallium-6828-31, and indium-111.11 The remarkable stability of the Zr-DFO complex was 
first reported in 1992 by Meijs et al. based on the affinity between Zr4+ and monohydroxamate 
ligands.19, 32 This landmark work proved that zirconium and DFO form a highly stable 1:1 complex, 




undergoing only minor demetallation in human serum. The first in vivo assessment of the Zr-DFO 
complex compared it with zirconium-89 citrate, chloride and oxalate salts. The use of the latter 
three salts corresponded with increased uptake of zirconium-89 in the bones of subjects, however 
Zr-DFO largely remained a stable complex and exhibited rapid clearance from the body.33 
However, migration of zirconium-89 to bones is of great concern as it results in a long-lived, 
gamma-emitting isotope being accumulated near the sensitive bone marrow tissue. More recent 
research has elucidated the mechanism for Zr-DFO demetallation, with molecular modelling of 
the complex indicating the simultaneous binding of two H2O molecules in the remaining 
coordination sites for zirconium-89 in a cis-conformation.34 It is thought that these water 
molecules may contribute to demetallation of the Zr-DFO complex by increasing complex lability. 
As a result, in vitro assessments of chelators focus on conditions which might induce complex 
dissociation: transchelation by other compounds, competition by other metal ions, and pH-
induced effects. A further useful property of DFO is its primary amine group, which facilitates 
binding to mAB.7 
 
The terminal amine of DFO allows for simple conjugation to antibodies or other targeting 
molecules while still forming stable complexes with chelated metals, a property known as 
bifunctionality.19 A series of papers by Meijs et al. reported the first Zr-DFO-protein conjugates; 
while in vivo stability was promising, accumulation of zirconium-89 in the kidneys, livers and bones 
of subjects was noted.35-36 While at first protein degradation was expected to be responsible for 
this accumulation, subsequent works found the SATA-SMCC linker used by the researchers 
(Figure 8, 1) was insufficiently stable at physiological pH.37 This led to the development of 
alternative linkers, the best of which was an N-succinyl linker developed by Verel et al (Figure 8, 
2).13 This linker improved on complex stability and has since found wide use.34, 38-39 However it 
does have shortfalls: conjugation of DFO to an antibody first requires chelation of Fe(III), which 
must then be removed by EDTA transchelation, representing challenging and redundant synthetic 




steps; further, while improvements in stability were observed compared to SATA-SMCC, 
zirconium-89 accumulation was still seen in subjects.14 The improvements observed did show 




Figure 8: 89Zr-DFO linker moieties: SATA-SMCC (1); N-succinyl (2); p-isothiocyanatobenzyl (3); 
squaramide (4), tetrazine (5), iodoacetamido- (6), bromoacetamido- (7), (N-maleimidomethyl)-
cyclohexane (8), 2-cyanobenzothiazole (9, 10). R = 89Zr-DFO. 
In the quest for a simpler radiolabelling procedure a new linker was pioneered - a p-
isothiocyanatobenzyl group which could react with lysine residues (Figure 8, 3). The conservation 
of stability between this and the N-succinyl linker, combined with the simpler synthesis of the 
former, led to the adoption of the p-isothiocyanatobenzyl linker as a standard.40-41 There is, 
however, some evidence that this linker strategy leads to aggregation of the mAB during the 




conjugation step.41 In vivo assessments of the 89Zr-DFO-p-isothiocyanatobenzyl-mAB system 
have shown similarity to the widely used gamma emitter 99mTc,42 and advantages over the gamma 
emitter 125I.43 Exploration of alternative linker strategies has continued to address the persistent 
issue of degradation and uptake of zirconium-89 into bones.  
 
The development of novel linker strategies for 89Zr-DFO has focussed on a need to increase 
stability and also ease of synthesis. An ethyl squaramide ester linker (Figure 8, 4) for DFO showed 
promising increases in tumour-to-bone uptake ratios compared to the p-isothiocyanatobenzyl 
linker.44 It was hypothesised that greater stability was imbued by association of the dione group 
of the linker with the zirconium ion; the oxygen donor character of the linker binds readily with 
zirconium-89, increasing the coordination of the complex to an octadentate system. The N-
succinyl linker was modified with the addition of a tetrazine group (Figure 8, 5) permitting 
conjugation to modified antibodies via “click” chemistry.45 This system undergoes rapid uptake in 
bone tissues of around 15% ID/g (injected dose per gram), suggesting that it is associated weakly 
with the 89Zr4+ ion. Tianinow et al. reported a set of 3 novel linkers to compare to the 
isothiocyanatobenzyl and N-succinyl groups: iodoacetamido-, bromoacetamido-, and 
maleimidocyclohexanyl moieties (Figure 8, 6 - 8), capable of reacting with cysteine residues in 
mAB.46 Of these, the maleimidocyclohexanyl linker showed the greatest uptake into tumours, 
lowest incubation time, and also a relatively high uptake into bone (10% ID/g). The acetamido-
linkers exhibited similar biodistribution to the maleimidocyclohexanyl linker with lower tumour 
uptake. The 2-cyanobenzothiazole linkers (Figure 8, 9 - 10) developed by Gao et al for coupling 
to cysteine residues showed good resistance to transchelation and reasonable stability in serum, 
but did not compare this novel linker to an established system to show relative stability.47 
 
Only a small number of clinical trials thus far have focussed on the performance of 89Zr-DFO-
mAB systems.18 The first reported study involved the injection of twenty late-stage cancer patients 




with a zirconium-DFO-N-succinyl-antibody conjugate - in this case, the CD44v6-specific antibody 
U36.48 The zirconium-conjugate system showed good sensitivity, no conjugate accumulation 
seen outside tumourous tissues and no adverse effects connected to the Zr-DFO system. Another 
pilot study in 2006 compared the biodistributions of 89Zr-DFO-Zevalin and 90Y-Zevalin, finding that 
tumour uptakes were similar for both conjugates.49 In a separate study, seven patients with 
advanced lung cancer were injected with a Zr-DFO-N-succinyl-bevacizumab, a mAB which 
targets the vascular endothelial growth factor receptor.50 A 4-fold increase in uptake at the 
tumours was observed compared to other tissues such as the lung, fat and muscles. However, 
high blood activity was observed during the 4-day scan, indicating that clearance of this system 
was low. 89Zr-DFO systems have further been clinically investigated in the detection of prostate 
cancer (conjugated to prostate-specific membrane antigen J591)51, rheumatoid arthritis and 
multiple sclerosis (conjugated to the anti-CD20 antibody rixumitab)52-53, and HER2-positive breast 
cancer (with trastuzumab)54, showing promising resolution and similar distributions to the 
unconjugated mABs. 
 
Current evidence indicates that 89Zr-DFO undergoes significant demetallation in vivo, with 
uptakes in bone tissues of around 10% ID/g regardless of the linker used. While 89Zr-DFO is 
rapidly cleared if the linker is cleaved, the lengthy circulation times of mAB all but ensure that 
89Zr-DFO-mAB conjugates will experience demetallation to some degree. The development of 
new linker strategies, as discussed above, has not led to substantial improvement. The 
development of alternative chelators has therefore been of great interest in order to improve on 
the characteristics of DFO.55 
 
  




1.3.2 Beyond DFO: novel chelator development  
Based on the success and limitations of DFO, routes to novel zirconium chelators have been 
varied. Focus has been placed on the use of alternative functional groups for binding, the increase 
in denticity to octadentate, and increasing preorganisation through the use of a macrocyclic 
chelator, or a combination of the three factors. 
1.3.2.1 Hexadentate chelators 
Due to the ready availability of DFO and its known limitations, little work has focussed on 
producing alternative hexadentate chelators for zirconium-89. The sole published development 
of a non-DFO, hexadentate chelator for zirconium-89 is that of YM103 (Figure 9), which displayed 
inferior characteristics compared to DFO.56 
 
Figure 9: The hexadentate zirconium chelator YM103.56 
1.3.2.2 Octadentate chelators 
Based on the observation that Zr4+ coordinates with 2 H2O molecules while bound by DFO, and 
the subsequent instability of the system in vivo, attempts have been made to improve the binding 
stability of the Zr-DFO complex by incorporating a fourth binding moiety to increase the 
coordination of the complex.  





Figure 10: Linear octadentate chelators of 89Zr: DFO* (1, X = CH2),57 oxo-DFO* (1, X = O),58-59 DFO-HOPO 
(2),60 chelators developed by Rousseau et al. (3, n = 1,2).61 
Incorporation of a fourth hydroxamate into DFO resulted in the promising DFO* ligand (Figure 10, 
1) developed by Patra et al. with a carboxylic acid terminus also incorporated for conjugation.57 
This compound displayed superior stability to 89Zr-DFO, resisting transchelation by DFO even at 
3000-fold concentration. Comparison of the trastuzumab conjugates of DFO and DFO* found use 
of the DFO* conjugate caused equivalent tumour uptake but lower zirconium-89 levels in organs 
and bones.62 DFO* can be prelabelled with zirconium-89 before mAB conjugation, while DFO-
mAB conjugates had to be prepared before radiolabelling. This suggests the stability of 89Zr-DFO-
mAB conjugates depends on coordination between linker molecules and 89Zr. DFO* exhibited 
very limited solubility in water; to allay this, modified versions containing ether groups have been 
synthesised.58-59 Conjugation of this oxo-DFO* compound has not been reported, with its activity 
in vivo remaining unknown. 
 
The affinity of zirconium-89 with DFO modified with a 1-hydroxy-2-pyridone group inserted at the 
N-terminus has been reported.60 This molecule, known as DFO-HOPO (Figure 10, 2), has good 




affinity for zirconium-89 and the complex displays improved in vitro stability and rapid clearance 
in vivo even compared to Zr-DFO.63 However, no bifunctional variant of this chelator has been 
reported thus far, which has prevented proper assessment of in vivo stability. In contrast, the 
tripodal tetrahydroxamates reported by Rosseau et al. (Figure 10, 3) underwent significant 
demetallation in comparison to their DFO-conjugated counterparts, with the effect of steric 
hindrance marked by the greater affinity of the longer-armed variant.61 
 
Figure 11: Linear hydroxypyridinone chelators of 89Zr: 3,4,3-(LI-1,2-HOPO) (4)64 and THPN (5).65 
Two novel octadentate, hydroxypyridinone-based chelators of zirconium have shown extremely 
promising results in challenge assays. 3,4,3-(LI-1,2-HOPO) (Figure 11, 3) shows remarkable in 
vitro stability when complexed with 89Zr, outperforming DFO in the presence of a library of 
biologically relevant metal ions and at lowered pH; a low bone tissue uptake was seen in in vivo 
experiments.64 The 89Zr-3,4,3-(LI-1,2-HOPO) complex performs well while conjugated to 
trastuzumab, again displaying a much lower bone uptake than the respective DFO conjugate.66 
However the synthesis of this chelator is challenging. The hydroxypyridinone zirconium chelator 
THPN (Figure 11, 4) displays rapid radiochemical complexation in excellent yield, and is resistant 
to transchelation and low pH. However, THPN has not yet been assessed in a conjugated system, 
meaning in vivo demetallation across a 7-day period remains yet unknown.65 
  




1.3.2.3 Macrocyclic chelators 
Several studies have focussed on synthesising zirconium chelators incorporating macrocyclic 
structures. While these are more challenging to synthesise than linear chelators, the increased 
organisation of the complexes can lead to more stable complexes. 
 
Figure 12: Macrocyclic chelators of 89Zr: library developed by Guérard et al.67 (1, n = 1, 2, 3), CTH36 (2),68 
triacetylfusarine-C (3), DFOT (4, y = 1) and PPDFOT (4, y = 2).69 
A set of linear and macrocyclic peptides of 28, 32 and 36 molecules each were rationally designed 
by Guérard et al. (Figure 12, 1).67 Both the 32 and 36-molecule systems displayed favourable 
properties, and the 36-member macrocycle displayed superior resistance to transchelation when 
compared to Zr-DFO. CTH36 (Figure 12, 2) is more resistant than DFO to transchelation in vitro 
and was conjugated efficiently; however no in vivo data was reported.68 The modified siderophore 
triacetylfusarine-C (Figure 12, 3) forms more stable complexes with zirconium-89 than DFO and 
shows substantial resistance to transchelation by both EDTA and DFO.70 No bone uptake was 
reported during original biodistribution studies. However, the molecule lacks a bifunctional handle 




and must be radiolabelled at high temperatures.71 A metal-templated synthesis has also been 
used to develop macrocyclic structural variants of DFO: DFOT and PPDFOT (Figure 12).69 Both 
macrocycles were resistant to transchelation by EDTA; the added molecular length did not result 
in a reduction in efficacy.67 
 
More recently, tetraazamacrocyclic chelators have been revisited as potential chelators for 
zirconium-89. Tetraazamacrocycles are commonly used in conjunction with other radiometals in 
therapy and diagnosis, such as indium-111, yttrium-90, copper-64, gallium-68 and lutetium-177; 
the most well-known chelator in this class is DOTA (Figure 13).72 DOTA and its derivatives DOTP 
and DOTAM have shown superior in vitro characteristics to DFO, with DOTA displaying superior 
in vivo characteristics; however these chelators require radiolabelling in specific conditions (with 
ZrCl4 rather than Zr(ox)2, and at 80° C).73 It is hypothesised that the carboxylate pendant arms 
present on DOTA bind more favourably to zirconium(IV) than the amino and phosphate groups in 
DOTAM and DOTP respectively. DOTA, however, is not a bifunctional chelator, a property which 
makes it unsuitable for use with mAB; several bifunctional variants of DOTA can be purchased 
(as in Figure 13),72 but the stability of these chelators complexed with zirconium-89 has yet to be 
assessed. The bifunctional, tetraazomacrocyclic chelator shown in Figure 13 (9) contains 
hydroxamate groups as its pendant arms.74 However, DFT calculations revealed that the nitrogen 
donors did not interact with zirconium-89 in chelation, and the resultant hexadentate chelation led 
to greater demetallation in vivo than seen with DFO, leading to 18.9% ID/g bone uptake.  
 
Hydroxypyridinones such as BPDETLysH22-2,3-HOPO (Figure 14), have been widely used to 
chelate other radiometals such as gallium-68. The 89Zr-BPDETLysH22-2,3-HOPO complex 
showed poor stability in serum, but in vivo showed similar biodistribution to 89Zr-DFO when both 
chelators were conjugated to trastuzumab.75  
 





Figure 13: Tetraazomacrocyclic chelators of zirconium-89; DOTP (4), DOTAM (5), DOTA (6), DOTA-GA 
(7), p-SCN-Bn-DOTA (8), L5 (9).74 
 
 
Figure 14: BPDETLysH22-2,3-HOPO (10)75 
  





Gallium-68 is used widely as a positron-emitter for PET imaging. It has a short half-life of around 
68 minutes, is very simple to produce with a 68Ge/68Ga generator, and is one of few short-lived 
radioisotopes that can be produced in this manner.27 Germanium-68 has a long half-life (271 d) 
making these generators long-lasting and relatively safe.9 These generators can be stored in 
hospitals to minimise transportation time, and with no cyclotron involved they require little capital 
investment. Gallium-68 decays by 89% positron emission to the stable 67Zn; however, the 
positrons have a substantially higher energy than zirconium-89, averaging 1899 keV.76 NETSPOT, 
a 68Ga somatostatin for diagnostic use, was approved in June 2016.77 
 
Generally, gallium exists as Ga(III), and between pH 3 and pH 7 forms insoluble Ga(OH)3 (Figure 
15); radiolabelling can occur within this range depending on the chelator used.9 Gallium(III) has 
an ionic radius of 0.62 Å, and coordinates in a similar fashion to Fe(III), with a preference for 
hexadentate chelation and oxygen donors.78 Similar to Zr(IV), catechol and hydroxamate ligands 
form particularly stable bonds with Ga(III). 
 
  
Figure 15: Speciation of Ga3+ at 25 °C.79 





Figure 16: Clinically used chelators of 68Ga.9, 78 
Gallium-68 has been studied with a variety of chelation strategies and in conjunction with a range 
of small molecules (Figure 16). DOTA and its derivatives are commonly used and can be labelled 
with gallium-68 at high temperatures (37 - 90° C).72 The smaller NOTA has a stronger affinity for 
gallium-68, but the extra charge on the Ga-DOTA complex gives it more favourable behaviour. 




Both these macrocycles bind gallium-68 due to its small atomic radius.80 The FDA-approved 
68Ga-containing therapeutic NETSPOT binds gallium-68 with a DOTA-TATE group. H2DEDPA 
has also shown promising results in vivo and in vitro in use with gallium-68,81-82 with good 
resistance to transchelation and rapid radiolabelling. HBED shows promising binding kinetics but 
are rarely used clinically. PCTA is a recently developed chelator which shows more promising 
labelling and stability attributes than DOTA.72 As the half-life of 68Ga is not suited to conjugation 
with mAB, it is more widely used with small peptide-based molecules for targeting receptors.80  
 
As noted above, there is some crossover between chelators used for zirconium-89 and gallium-
68: both are hard acids which bind preferentially to oxygen or nitrogen donors. Triacetylfusarine-
C and desferrioxamine-E form the most stable gallium-68 complexes in serum and in the 
presence of competing chelators.29-30 Due to the rapid decomposition of gallium-68 into the stable 
zinc-67, there is little risk associated with its release in the body; there is therefore potential to 
develop chelators with improved binding potential for both zirconium-89 and gallium-68.  




1.5 Overview and project aims 
DFO is a highly effective chelator of zirconium-89 that has been used with some success in 
clinical trials, yet further improvements in complex stability would be desirable. No zirconium-89-
based therapeutic has yet been approved for medical use, and the consensus is that 89Zr-DFO is 
kinetically unstable in vivo.11 This instability is thought to be due to molecular strain caused by 
DFO-metal complexation, and simultaneous coordination of two H2O molecules to 89Zr4+ 
coincidentally to DFO, increasing the lability of the complex.34 The result of this is demetallation 
of the complex, resulting in the accumulation of zirconium-89 in bone tissues ranging from 0.5 – 
15% ID/g. The effects of this accumulation have yet to be measured in a clinical trial, but damage 
to bone marrow is a hypothetical risk. Therefore, measures must be taken to improve upon the 
stability of DFO. Modification of the linker strategy has, in some cases, led to a mild improvement 
in stability, but generally at the expense of synthetic simplicity. Of the alternative chelators for 
zirconium-89, DOTA,73 DFO*,57 and 3,4,3-(LI-1,2-HOPO)64 are the best candidates thus far; each 
has been examined in a conjugated system and has proven stability compared to their respective 
DFO conjugates. This proves that a variety of approaches to the rational design of a new 89Zr 
chelator are feasible. The goals of the synthesis of new and improved chelators for 89Zr are thus: 
 
• A chelator which demonstrates improved stability of the 89Zr-complex in vitro and in vivo, 
achieved by the reduction of molecular strain and the addition of a fourth bidentate 
binding moiety; 
• A chelator which can be synthesised in good yield, and which can be radiolabelled in mild 
conditions;  
• A chelator featuring a bifunctional handle by which conjugation to mAB is possible. 
 
The hydroxamate group remains the best candidate for novel zirconium chelators due to ease of 
synthesis in comparison with the hydroxypyridinones and allowing milder radiolabelling conditions 




in comparison with the tetraazamacrocycles. Improving on the stability of Zr-DFO necessitates 
the inclusion of a fourth hydroxamate moiety. Both cyclic and acyclic hydroxamate chelators have 
shown promising results; macrocyclic chelators require higher temperatures for radiolabelling, 
and have slightly more complicated syntheses, however this is usually rewarded with increased 
complex stability from ligand preorganisation. Chelators with a length shorter than 32 molecules 
do not appear to form stable complexes with zirconium, but chelators with lengths of between 36 
and 48 atoms have reported improvements in binding.67-69 The design should seek to minimise 
molecular strain while introducing a fourth hydroxamate binding moiety and maintaining high 
solubility. 
 
Based on the above criteria, a set of novel chelators has been designed (Figure 17). These 
chelators are comprised of repeating 11-molecule subunits, similar to DFO, and feature two 
protected bifunctional handles. While linear chelators generally show inferior binding 
characteristics compared to macrocycles, these chelators have the potential for macrocyclisation   
through these bifunctional handles. The incorporation of an α-amino acid in the structure imbues 
functionality, whereby amino acids with polar side chains could be substituted for the original 
glycine moiety in order to increase the solubility. Of interest in this synthesis is the investigation 
of the reported instability of α-amino acid-based hydroxamate chelators.68 No detailed 
experimental work on such a structure has been published, and more thorough investigation is 
warranted. The focus of this project will be to move toward a synthesis of a zirconium-89 chelator 
incorporating α-amino acid moieties, with radiochemical assessment of the products of synthesis. 
 





Figure 17: The primary target molecules of this project, the tri- and tetra-hydroxamate chelators 8 and 10. 
 
  









2 Attempted syntheses of novel zirconium-89 chelators 
2.1 Chelator design 
The novel chelators 8 and 10 were chosen as target molecules for this project. Both are 
structurally similar to DFO yet can be synthesised and functionalised by traditional peptide 
synthesis. Hydroxamate-based chelators are generally synthesised via solution-phase 
synthesis rather than solid-phase peptide synthesis. However, the peptide-based structure of 8 
and 10 allow use of either method, with a retrosynthetic analysis shown in Scheme 1.  
 
A modular synthesis was proposed given that both molecules are comprised of different 
numbers of repeating subunits. This then allows successive, orthogonal deprotection reactions 
and peptide coupling reactions. Furthermore, the required starting materials are commercially 
available. Orthogonal protecting groups are required to prevent undesired reactions at the 
amine, carboxylic acid, and hydroxylamine groups. A benzyl ether group (OBn) was chosen to 
protect the hydroxylamine group as it is stable in both acidic and basic conditions and is 
removed by hydrogenation. 
 
Like DFO, chelators 8 and 10 are bifunctional, with amine and carboxylic acid termini to allow 
macrocyclisation or conjugation to mAB. Substitution of glycine for another α-amino acid would 
allow for further functionalisation. There remain questions around the feasibility of the use of α-
amino acids in zirconium-89 chelators, and this will be assessed.68 
 





Scheme 1: Retrosynthetic analysis of novel chelators 8 and 10. 
  




2.2 Solid-phase approach to novel chelators 
 
Scheme 2: Proposed synthesis of modular subunit 3.1 by solution-phase peptide synthesis 
The peptide subunit 3.1 was synthesised via solution-phase peptide synthesis in preparation 
for the solid-phase modular synthesis of 8 and 10 (Scheme 2). N-Alkylation of ethyl 7-bromo 
heptanoate by benzyloxy(tert-butoxycarbonyl)amine was performed in the presence of NaH 
based on the method reported (step 1, Scheme 2).83 Reagent ratios were modified as per  
Table 1 in order to improve the yield of the reaction, with some degradation of 7-bromo ethyl 
heptanoate observed by TLC over the course of the reaction. The optimum conditions proved 
to be an excess of 1.1 eq. of ethyl 7-bromo heptanoate, as shown in line 7 of Table 1, with the 




course of the reaction followed by TLC. Reaction scale-up was achieved by performing the 
reaction at 60 °C (see line 10).67 The crude product was separated by silica-based column 
chromatography in either 2:8 ethyl acetate/hexane or 1:9 acetone:hexane to give compound 1 
in yields of 44 - 81%. Analysis by 1HNMR revealed slight upfield translation of the triplet 
resonance at 3.40 ppm and singlet resonance at 4.82 ppm due to the N-alkylation of 
benzyloxy(tert-butoxycarbonyl)amine. Further analysis of the 1HNMR spectrum is provided in 
section 2.5. 
Table 1: Optimisation data for the N-alkylation of ethyl 7-bromo heptanoate by benzyloxy(tert-
butoxycarbonyl)amine to form 1. Line 7 (grey) showed the maximum yield while line 10 represents a 
scaled-up reaction. 
Experiment no. Boc-NH-OBn 
(eq) 
NaH (eq.) C9H17O2Br (eq.) Yield (%) 
1 1.0 1.5 1.0 50 
2 1.0 1.5 1.0 44 
3 1.0 1.1 1.3 69 
4 1.0 1.1 1.0 58 
5 1.0 1.2 1.1 63 
6 1.0 1.2 1.1 77 
7 1.0 1.2 1.1 81 
8 1.0 1.2 1.0 59 
9 1.0 1.5 1.2 45 
10 1.0 1.0 1.3 64 
 
Compound 1 was then treated with 20% TFA/DCM at room temperature in order to remove the 
Boc group to yield the amine 2 in quantitative yield without further purification (Scheme 2). The 
reaction was monitored by TLC to confirm complete consumption of the starting material. An 
analysis of the 1HNMR spectrum revealed the absence of a singlet resonance at 1.51 ppm as 
was observed in compound 1, corresponding to the Boc group. 
 
The free amine 2 was coupled with Fmoc-glycine in the presence of 1 eq. HATU, 4 eq. DIPEA, 
and DMF to give 3.1 in 69% yield, as per step 3 in Scheme 2. The reaction was monitored by 
TLC and the product separated by column chromatography in 3:7 ethyl acetate/hexane. The 




product was analysed by 1HNMR to reveal new resonances: a singlet at 4.11 ppm 
(corresponding to glycine α-protons); a triplet at 4.26 ppm; a doublet at 4.39 ppm; and a multiplet 
at 7.27 – 7.80 ppm (corresponding to the Fmoc group).  
 
Deprotection of the ethyl ester of 3.1 was attempted by the addition of 3 eq. LiOH in THF/MeOH, 
as per step 4 of Scheme 2. However, the desired product 4c was not isolated; analysis by 
1HNMR showed the absence of a key multiplet resonance between 7.50 and 7.80 ppm, 
indicating the simultaneous cleavage of the Fmoc group. Selective deprotection was attempted 
by the dissolution of 3.1 in a solution of 0.5M CaCl2 in 7:3 IPA/H2O and addition of 4 eq. LiOH 
at room temperature, but the reaction did not proceed.84 To another sample of 3.1 was added 5 
eq. MgI2 in THF and the solution heated to 120 °C by microwave,85 but again compound 4.1a 
could not be isolated. The failure to complete this synthetic step prompted the use of an 
alternative synthetic route (Scheme 3, Scheme 4). 
2.3 Solution-phase approach 
 
Scheme 3: Synthesis of subunit 3 by solution-phase peptide synthesis. 
The synthetic route was altered as summarised in Scheme 3. Compounds 1 and 2 were 
synthesised as in the previous section. The free amine 2 was subsequently coupled with Boc-
glycine in the presence of 1.2 equivalents of HATU, 4 – 5 eq. DIPEA, and DMF. The reaction 
was monitored by TLC and the product separated by column chromatography in 3:7 ethyl 




acetate/hexane, to give compound 3 in 52 – 78% yield. Analysis by 1HNMR revealed diagnostic 
singlet resonances at 3.97 ppm and 1.46 ppm corresponding to the glycine α-protons and Boc 
group respectively. 
 
Scheme 4: Modular synthesis of compound 8 by solution-phase peptide synthesis.  
A sample of compound 3 was treated with 20% TFA/DCM at room temperature in order to 
remove the Boc group as per Scheme 4, and this gave compound 4b in quantitative yield without 
the need for further purification. The reaction was monitored by TLC to confirm consumption of 




the starting material; further analysis of 1HNMR revealed the absence of the key singlet 
resonance at 1.46 ppm indicating removal of the Boc group. 
A separate sample of compound 3 was combined with LiOH in THF to deprotect the ethyl ester 
as per Scheme 4; the reaction was cooled in ice for 15 minutes and raised to room temperature 
for the remainder of the duration. The reaction was monitored by TLC to confirm consumption 
of the starting material; this analysis revealed the formation of several side-products. In contrast 
to similar reported reactions,68 starting material was present in the reaction mixture up until the 
12-hour mark. Different bases (LiOH and NaOH), quantities of base (between 1.1 and 6 eq.), 
solvent systems (THF, MeOH and H2O) and reaction times (9 – 24 h) were trialled to optimise 
the reaction as per Table 2; the optimum conditions trialled are shown in line 5. Crude products 
of this reaction were either used without further separation or purified with column 
chromatography, using 1:1 ethyl acetate/hexane with 1% acetic acid or 4:96 MeOH/DCM, giving 
compound 4a in yields of between 8% and 44%. Analysis by 1HNMR showed the absence of 
key resonances: a quartet at 4.10 ppm and a triplet at 1.26 ppm, corresponding to the loss of 
the ethyl ester. 
Table 2: Optimisation conditions trialled for the deprotection of 3 to give 4a. Yields marked with an 
asterisk (*) indicate the crude product was not purified by chromatography and yield was estimated by 
1HNMR (by peak intensity) and HPLC (by peak intensity). 
Base Base (eq.) Solvent Reaction time 
(h) 
Yield (%) 
NaOH 1.1 MeOH/H2O 20h 15% 
LiOH 3 THF/H2O 20h 0% 
LiOH 4 THF/H2O 20h 35% 
LiOH 6 THF/H2O 20h 8% - 40% 
LiOH 6 THF/H2O 9h 44%* 
LiOH 3 THF/MeOH/H2O 24h 27% 
 
Analysis of the reaction mixture by HPLC revealed the production of side-products increased 
gradually over 10 hours (Table 3, Figure 18). Comparison between HPLC traces of this sample 
and another reacted for 21 hours revealed a significant decrease in the yield of 4a after 21 hours 




and an increased range of side products (Appendix, Spectrum 43 and Spectrum 44). Analysis 
of crude reaction samples by 1HNMR consistently revealed the appearance of a triplet 
resonance at 3.2 ppm, suggesting that a competing reaction was occurring simultaneously. 
Table 3: Deesterification of compound 3 over time as measured by HPLC. Component proportions 
determined by integration of HPLC trace. Analysis was performed using a gradient of 10-100% MeOH 






































Figure 18: Change in key components of reaction mixture over time for deesterification reaction of 
compound 3. with proportions estimated by integration of HPLC traces. The starting material, compound 
3, eluted at 20.9 mins; the desired product, compound 4a, eluted at 18.2 minutes. Peaks at 13.7 and 
13.2 mins represent unknown by-products. Analysis was performed using a gradient of 10-100% MeOH 
over 15 minutes. 
  




20.9 18.2 15.8 14.3 13.7 13.2 
0 100 0 0 0 0 0 
30 97 3 0 0 0 0 
120 85.57 11.78 0 0 1.24 1.41 
240 68.34 21.89 2 1.39 1.7 4.68 
360 41.75 25.87 0 2.71 8.12 10.95 
540 12.32 43.86 6.42 3.88 11.07 22.45 




Acid 4a was subsequently coupled to amine 4b in the presence of HATU (1.1 eq.), DIPEA (4 – 
5 eq.) and DMF, as per Scheme 4. The reaction was monitored by TLC and the crude product 
was purified by column chromatography in either 1:1 ethyl acetate/hexane or 4:96 MeOH/DCM. 
Compound 5 was subsequently isolated with yields of between 11 - 21%. Analysis by 1HNMR 
revealed key resonances: a singlet at 1.46 ppm; a quartet at 4.10 ppm, and a triplet at 1.26 ppm, 
corresponding to the Boc and ethyl ester groups respectively. Other observations made using 
1HNMR will be discussed further in section 2.5. 
 
Compound 5 was then treated with 20% TFA in DCM at room temperature to cleave the Boc 
protecting group, as per Scheme 4. The reaction was monitored by TLC to confirm complete 
consumption of the starting material. This gave compound 6b in quantitative yield after 2 hours. 
Analysis by 1HNMR revealed the absence of the key singlet resonance at 1.46 ppm, 
corresponding to the Boc group. 
 
Compound 6b was then coupled to compound 4a in the presence of HATU (1.1 eq.), DIPEA (4 
eq.) and DMF at room temperature for 48 hours, as per Scheme 4. The reaction was monitored 
by TLC and attempted separation by column chromatography in 5:95 MeOH/DCM gave a 
sample containing compounds 7, 7.1 and 7.2 (Figure 19) based on HRMS analysis. Mass peaks 
corresponding to the formulae of each compound in the sample were identified by HRMS with 
detected masses of 1017.6085, 784.4766 and 551.3237. Analysis by 1HNMR revealed the 
presence of the singlet resonance at 1.46 ppm, corresponding to the Boc group of all 
compounds. The integrations of the multiplet resonances at 1.55 – 1.70 ppm and 1.31 – 1.40 
ppm also suggested a mixture of several compounds; this will be discussed further in section 
2.5. The product was used without further purification with the option to resolve product purity 
after the following step.  
 




The mixture containing compounds 7, 7.1 and 7.2 was subsequently hydrogenated over Pd/C 
in ethyl acetate at room temperature to cleave the benzyl ether protecting group, as per Scheme 
4. The reaction was monitored by TLC and the product used without further purification. Analysis 
by TLC showed a spot of lower Rf, and analysis by 1HNMR revealed the absence of the multiplet 
resonance between 7.3 – 7.5 and the singlet at 4.9 ppm, indicating complete cleavage of the 
benzyl protecting group. However, analysis by 1HNMR showed markedly low intensity for many 
signals relative to the ethyl ester and Boc protecting groups, and analysis by HRMS returned a 
sole peak at 483.24. Further analysis by LRMS revealed two peaks at 461.3 and 483.3. 
Subsequent analyses by COSY, TOCSY and ROESY led to the proposition of an alternative 
structure 8.1 (Figure 19); spectral evidence will be discussed further in section 2.5. However, it 
is postulated that compound 7 underwent an aspartamide-like reaction and while details remain 
unclear, there are reports of this occurring on hydroxamate-containing compounds under both 
acidic and basic conditions.86 The observed masses of 461.3 and 483.3 are consistent with the 
[M+H] and [M+Na] peaks of compound 8.1 (Figure 19). It was determined that the product of 
this reaction was compound 8.1.  
 
Figure 19: Products of decomposition; 7.1 and 7.2 observed in the mass spectrum of compound 7, while 
8.1 is the sole compound observed after the hydrogenation of compound 7. 
 





Scheme 5: Attempted scheme for synthesis of tetrameric chelator 10.  
A sample of compound 5 was treated with 1M LiOH solution in THF/MeOH as per Scheme 5 in 
order to hydrolyse the ethyl ester. The reaction was monitored by TLC which revealed the 
formation of multiple side-products. Separation of the crude product was attempted with column 
chromatography, however no isolable sample of compound 6a was obtained. A reaction was 
attempted between the crude product of this reaction (used without further purification) and 
compound 6b in the presence of HATU, DIPEA and DMF; however this was unsuccessful.  
  




2.4 Alternative approach: synthesis of chelator containing β-amino acid 
 
 
Scheme 6: Scheme for synthesis of compound 15 by solid-phase peptide synthesis 
After the unsuccessful syntheses of compounds 8 and 10, a synthesis of compound 14 was 
attempted to directly assess the validity of incorporating β-alanine rather than glycine into a 
hydroxamate chelator. While Seibold et al. have successfully synthesised 36-member 
macrocyclic chelators with a similar backbone (alternating β-alanine and N-hydroxyl butanoic 




acid subunits), no synthesis of chelators containing α-amino acids was reported.68 The 
additional terminal β-alanine group was included to allow more efficient loading onto resin.  
 
Synthesis began with synthesis of compound 1 as reported in section 2.1 by the N-alkylation of 
ethyl 7-bromoheptanoate (Scheme 6). Following this, compound 1 was deprotected on 
treatment with 3M HCl in acetone by the reported method87 to remove the ethyl ester and Boc 
protecting groups, as per Scheme 6. The reaction was monitored by TLC and the crude product 
11 was used without further purification. Analysis by 1HNMR revealed the absence of several 
resonances: a singlet at 1.51 ppm, a triplet at 1.26 ppm and a quartet at 4.10 ppm, 
corresponding to the Boc and ethyl ester groups. 
 
The mixture containing compound 11 was then coupled to Fmoc-β-Alanine in the presence of 
HATU (1.0 eq.), DIPEA (4.0 eq.) and DMF, as per Scheme 6. The reaction was monitored by 
TLC and the crude product purified by reverse-phase column chromatography using 7:3 
ACN/H2O, to give compound 12 in 25% yield. Analysis by 1HNMR revealed resonances at 2.65 
and 3.48 ppm due to the β-alanine group, which were conserved from analysis of the starting 
material.  
 
2-chlorotrityl resin was pre-coupled to Fmoc-β-Alanine in a solution of DCM and DIPEA (5 eq.), 
leading to a calculated loading of 0.44mol/g. The modified resin (0.1 mmol) was then incubated 
with a solution of compound 12 (0.3 mmol), PyOxim (0.3 mmol), DIPEA (1.5 mmol) and DMF 
(10 mL) as per Scheme 6, and agitated occasionally for 6 hours. Following this, the extent of 
coupling was determined with the Kaiser test.88 Cleavage of the Fmoc-protecting group was 
achieved by addition of 0.1M HOBt in 20% piperidine/DMF. This process was repeated three 
times before final cleavage of the resin by addition of 95/2.5/2.5 TFA/TIPS/H2O. The product 
was collected and purified by semi-preparative HPLC, to give compound 14 in a mass of 10 mg. 




Analysis by mass spectroscopy identified a peak of mass 1002.8 m/z, corresponding to the 
formula of the desired product. 
2.5 Spectral analyses 
Due to the modular nature of the above syntheses, there was a high degree of similarity between 
1HNMR spectra for each novel compound. Selected spectra are contained in this section while 
full spectra are provided in Appendix 5.2. 
 
Figure 20: Compound 1 
 
Spectrum 1: Complete 1HNMR spectrum for compound 1 in CDCl3. 
Analysis of a sample from the N-alkylation of ethyl 7-bromo heptanoate by 1HNMR (Figure 20) 
(Spectrum 1) revealed a number of key resonances. Firstly, the singlet at 1.51 ppm, the triplet 
at 1.25 and the quartet at 4.10 ppm corresponded to the Boc and ethyl ester group (Spectrum 
2, Spectrum 3).  





Spectrum 2: 1HNMR resonance corresponding to the Boc protecting group. 
 
 
Spectrum 3 (right): 1HNMR resonances corresponding to the ethyl ester group. 
The appearance of the singlet at 4.82 ppm and the multiplet at 7.33 - 7.41 ppm, corresponding 
to the methyl and aromatic protons of the benzyl ether protecting group, confirmed synthesis of 
compound 1 (Spectrum 4). These resonances integrated at a ratio of 2:5. 





Spectrum 4: 1HNMR resonances corresponding to benzyl ether protecting group of compound 1. 
The triplet resonances at 2.27 ppm and 3.39 ppm corresponded to methylene groups adjacent 
to the carboxyl and amine groups respectively (Spectrum 5) and integrated with a ratio of 1:1. 
 
 
Spectrum 5: 1HNMR resonances corresponding to methylene groups adjacent to the amine (R2N-CH2-
CH2, 3.39 ppm) and carboxyl (CH2-CH2-COO, 2.27 ppm) groups of compound 1. 
 





Spectrum 6: 1HNMR resonances corresponding to central methylene groups in alkyl chain of compound 
1; CH2-CH2-CH2-CH2 = 1.32 ppm, CH2-CH2-CH2-CH2 = 1.62 ppm. 
Multiplet resonances at 1.57 – 1.64 ppm and 1.27 – 1.35 ppm corresponded to the four central 
methylene groups in the alkyl chain, which formed two rough multiplets that integrated at a ratio 
of 1:1. 





Figure 21: Structure of compounds 2 (left) and 3 (right) 
Analysis by 1HNMR of a sample from the treatment of compound 1 with TFA/DCM (Figure 21) 
revealed the absence of the singlet resonance at 1.51 ppm, indicating complete cleavage of the 
Boc group; the triplet resonance at 3.39 ppm was replaced with a resonance at 3.31 ppm, 
indicating a change in character of the amine group from tertiary to secondary (Spectrum 18).  
 
Analysis by 1HNMR of a sample from the coupling of compound 2 to Boc-glycine (Figure 21) 
revealed new singlet resonances at 3.97 ppm and 1.46 ppm, corresponding to the α-protons of 
the glycine moiety (Spectrum 7) and the Boc group respectively. The triplet resonance at 3.31 
ppm (visualised in the 1HNMR spectrum of compound 2) was no longer visible, with a broad 
triplet appearing at 3.67 ppm; as the former was assigned to the methylene group adjacent to 
the secondary amine, this change was attributed to the formation of an amide from this 
secondary amine, indicating a successful formation of compound 3. 
 
Spectrum 7: 1HNMR signals corresponding to the α-proton signal (blue) and the R2N-CH2-CH2 group 
(red) of compound 3.  





Figure 22: Compounds 4a (left) and 4b (right) 
Analysis by 1HNMR of a sample from the treatment of compound 3 with TFA/DCM revealed the 
absence of the singlet resonance at 1.46 ppm indicating complete cleavage of the Boc group 
(Spectrum 21).  
 
Meanwhile, analyses of crude samples from the hydrolysis of the ethyl ester of compound 3 to 
form 4a (Figure 22) by 1HNMR indicated unexpected changes in resonances. In particular, the 
signals corresponding to the benzyl ether groups (the multiplet at 7.30 – 7.50 ppm and singlet 
at 4.70 ppm) were of lower intensity compared to other resonances (Spectrum 8). The triplet 
resonance at 3.67 ppm also displayed a decreased intensity with a new triplet resonance of 
equivalent intensity appearing at around 3.2 ppm. Following purification of the sample, the triplet 
resonance at 3.2 ppm was absent, as were the triplet at 1.24 and the quartet at 4.10 which 
indicated successful cleavage of the ethyl ester and successful isolation of compound 4a 
(Spectrum 9). Broadening of the singlet at 4.08 ppm and poor resolution of the triplet at 3.64 
ppm was observed; the former likely due to the pair of glycine α-protons. 





Spectrum 8: 1HNMR spectrum for a crude sample from the attempted deesterification of compound 3. 
The decreased intensity of the resonances at 7.3 - 7.5 ppm and 4.6 ppm (corresponding to benzyl ether 
groups) indicate some change in these groups. 
 
Spectrum 9: Partial 1HNMR spectrum for compound 4a. The disappearance of the resonances at 1.24 
ppm and 4.10 ppm indicates complete cleavage of the ethyl ester. 
  






Figure 23: Compounds 5 (above) and 6b (below) 
1HNMR analysis of a sample from the coupling between 4a and 4b revealed key resonances: 
the triplet at 1.26 ppm, the quartet at 4.10 ppm, and the singlet at 1.46 ppm. These 
corresponded to the ethyl ester and Boc group respectively. Several other resonances were 
roughly doubled in intensity and somewhat broadened; this was noticed for the multiplets at 
7.38 – 7.46 ppm, 1.51-1.69 ppm and 1.26-1.40 ppm, and the triplets at 3.67 and 2.29 ppm. The 
relative increase in intensity of these signals compared to those of the terminal protecting 
groups (as highlighted above) suggested a successful dimerisation of the molecule. An 
additional singlet resonance was observed at 4.09 ppm (co-incident with the quartet at 4.10 
ppm), which was thought to correspond to the additional set of glycine α-protons (Spectrum 10). 
These factors combined with HRMS data suggested the successful formation of compound 5 
(Figure 23). 
 
Spectrum 10: Partial 1HNMR spectrum of compound 5 showing α-proton resonances (red). 
Analysis by 1HNMR of a sample from the treatment of compound 5 with TFA/DCM revealed the 
absence of the resonance at 1.46 (s) ppm, indicating cleavage of the Boc group (Spectrum 23) 
and the successful formation of compound 6b (Figure 23). 





Figure 24: Compound 7. 
Analysis by HRMS of a sample from the attempted coupling between 4a and 6b revealed a 
mass at 1017.6085 m.u., indicating the presence of the desired product 7 (Figure 24). However, 
there were additional peaks present at 784.4766, 551.3237 and 280.1998 m.u. (Spectrum 50), 
indicating a mixture of compounds. These masses are consistent with compounds 7.1, 7.2 
(Figure 19), and 2. Analysis by 1HNMR revealed a triplet at 1.23 ppm, a multiplet at 4.05 – 4.17 
ppm, singlets at 3.94 ppm, 3.75 ppm and 1.46 ppm which correspond to the ethyl ester group, 
α-protons, and the Boc group respectively, and displayed the expected integrations. The 
resonances corresponding to the hexanoate components of the molecule (i.e. multiplet 
resonance at 7.45 - 7.40 ppm, the singlet at 4.95 ppm, the triplets at 3.68 ppm and 2.29 ppm, 
and the multiplets at 1.55 – 1.70 ppm and 1.31 – 1.40 ppm) displayed lower intensity than 
predicted (Spectrum 24). The loss of these alkyl chains combined with the aberrant mass 
signals suggest a a mixture of 7, 7.1 and 7.2 (Figure 19).  
 
Analysis of a number of samples from the attempted preparation of compound 8 by 1HNMR 
showed the absence of the multiplet resonance at 7.3 – 7.5 ppm and the singlet at ~4.8 ppm, 
indicating removal of the benzyl ether group (Spectrum 25). A number of resonances were of 
lower than expected intensity, particularly the triplets at 3.46 ppm and 2.26 ppm, and the 
multiplets at 1.43 – 1.55 ppm and 1.19 – 1.30  ppm. The presence of grease resulted in 
additional peaks (a triplet at 0.85 ppm and a singlet at 1.23 ppm). Analysis of the sample by 
mass spectroscopy detected molecules of mass 461.3 and 483.3 m.u.  





Spectrum 11: Partial COSY 1HNMR spectrum of compound 8.1 showing coupling between amide peaks 
and α-proton peaks. 
Samples from the attempted preparation of compound 8 were further analysed by 2D 1HNMR. 
COSY 1HNMR (Spectrum 11) showed a crosspeak between resonances at 3.57 ppm and 6.97 
ppm, 3.75 ppm and 8.01 ppm, and 3.97 ppm and 7.87 ppm. The broad doublet resonances at 
3.57, 3.75 and 3.97 ppm displayed chemical shifts roughly corresponding  to glycine α-protons 
in the preceding molecules, while the broad triplet resonances at 6.97, 7.87 and 8.01 ppm were 
visible only when experiments were undertaken in DMSO, but had chemical shifts in the 
expected range of amide protons. No other crosspeaks were revealed by the above COSY 
experiment for these resonances, suggesting that these resonances corresponded to the three 
groups of α-protons and the three amides respectively of each glycine moiety. Further analysis 
by ROESY 1HNMR of the same sample showed crosspeaks between the same resonances as 
listed above, as well as additional crosspeaks between the doublet at 3.57 and the triplet at 8.01 
ppm, and between the doublet at 3.75 and the triplet at 7.87 ppm (Spectrum 12, red). This 
suggests that two distinct glycine moieties are adjacent to two amide groups each. The above 




data combined with the HRMS data for the same samples suggests the formation of an 
alternative product: compound 8.1, which has a calculated mass of 460.25 (Figure 25). The 
absence of peaks representing spatial correlation between amides and the alkyl chain (Figure 
25, red) supports this hypothesis. 
 
 
Spectrum 12: Partial ROESY 1HNMR spectrum of compound 8.1 showing coupling between amide 
peaks and α-proton peaks; peaks unique to ROESY spectrum are highlighted in red. 
 
Figure 25: Compound 8, with diagnostic group for compound 8 shown highlighted in red, and 
















Figure 26: Compounds 11, 12 and 14. 
1HNMR analysis of a crude sample from hydrolysis of the ethyl ester 1 to form compound 11 
(Spectrum 13) revealed the absence of a singlet resonance at 1.51 ppm, indicating complete 
cleavage of the Boc group. The quartet resonance at 4.11 ppm and the triplet at 1.24 ppm 
corresponding to the ethyl ester group were still present, but with significantly reduced intensity, 
indicating that approximately 80% of the sample had undergone hydrolysis. The triplet 
resonance at 3.40 ppm was replaced by another at 3.35 ppm, indicating the change in character 
of the tertiary amine to a secondary amine. Two coincident triplet resonances were present 
between 2.28 – 2.35 ppm due to partial hydrolysis of the ethyl ester in the sample. 
 
 
Spectrum 13: Partial 1HNMR spectrum of compound 11. 
  




Analysis of a sample from the coupling between 11 and Fmoc-β-Alanine to form the intermediate 
12 (Figure 26) revealed several resonances – a multiplet at 7.29 – 7.79 ppm, a doublet at 4.36 
ppm and a triplet at 4.21 ppm, corresponding to the Fmoc group, as well as multiplets at 3.48 
ppm and 2.65 ppm, corresponding to the α- and β-protons of β-alanine; these additional signals 
suggest successful coupling of the Fmoc-β-alanine moiety (Spectrum 14). The triplet resonance 




Spectrum 14: Partial 1HNMR spectrum of compound 12. 
Analysis of a sample from the attempted synthesis of compound 14 by 1HNMR revealed a range 
of key resonances (Spectrum 16). Three new resonances – two triplets at 7.83 and 7.79 ppm 
and a multiplet at 7.76 ppm - were apparent, with a total multiplicity suggesting these were 
amide protons. Several resonances were conspicuously absent including doublets at 7.77 ppm, 
7.60 ppm, and 4.36 ppm and a triplet at 4.21 ppm, indicating cleavage of the Fmoc group. 
Resonances including the multiplet at 7.33 – 7.46 ppm, and singlets at 4.86 ppm and 4.81 ppm 
corresponded to the benzyl ether groups. Multiplets at 3.17 – 3.26 ppm and 2.95 – 3.04 ppm 
corresponded to the eight β-protons of β-alanine, and multiplets at 2.76 – 2.84 ppm and 2.51 – 
2.58 ppm, and a triplet at 2.35 ppm corresponded to the eight α-protons. Analysis by TOCSY 
1HNMR allowed assignment of amide and β-alanine protons, as this identified which signals 
were located within the same spin systems. Further analysis by ROESY 1HNMR (Spectrum 15) 




identified a crosspeak between the suspected amide protons at 7.79 ppm and alkyl protons at 
2.01 ppm. The visualisation of this crosspeak through ROESY but not TOCSY suggested that 
these resonances were located in different spin systems, confirming that the molecule featured 
β-alanine and N-hexanoic acid residues in an alternating fashion; this crosspeak was not 




Spectrum 15: Partial ROESY 1HNMR spectrum of compound 14 indicating coupling between amide 
and methylene protons at (2.01, 7.79) ppm. 
 
Spectrum 16: Partial 1HNMR spectrum of compound 14. Resonances at 0.84 and 1.22 ppm are due to 
grease impurities. 




The target molecules 8 and 10 were unable to be synthesised, with some evidence of 
intramolecular degradation. Compound 14 was successfully synthesised and characterised, 
suggesting the inclusion of α-amino acids in the structure of hydroxamate-based chelators leads 
to instability. Compound 8.1 was isolated as a pure compound and could be examined 
radiochemically.  
  









3 Radiolabelling and stability assessment of novel chelator 
3.1 Zirconium-89: Radiolabelling and challenge assays 
The original target molecules, compounds 8 and 10, were not successfully synthesised. Instead, 
compound 8.1 was isolated in sufficient purity to examine its radiochemical properties. Previous 
studies by Guérard et al. optimised the structure of zirconium bound to the simplest hydroxamate 
subunits - acetohydroxamic acids – using computational and experimental methods.23,90 89Zr(ox)2 
was incubated with acetohydroxamic acid (AHA), N-methyl acetohydroxamic acid (Me-AHA) and 
DFO to assess the potential of each chelator to displace oxalic acid. The authors found that, after 
30 minutes, AHA and Me-AHA had only chelated 3.5% and 20% of the 89Zr in solution, compared 
to 99% for DFO.23 This validated their hypothesis that the effect of the N-methyl substituent was 
pronounced, yet low overall binding was observed for the monohydroxamate species.  
 
Figure 27: DFO, N-methyl acetohydroxamic acid, and compound 8.1. 
Compound 8.1 features several additional donor atoms compared to Me-AHA, which could 
feasibly facilitate binding of a greater denticity. While molecule 8.1 lacks the organisation of DFO, 
and will be less resistant to transchelation, it is of interest to assess the radiochemical stability of 
this complex.  
 
Radiochemical assessment of chelators is performed by incubation of a chelator with a radiometal 
over a short period, after which the radiolabelled chelators are then subject to challenge by 
biologically relevant conditions. These conditions generally focus on biologically relevant criteria: 
incubation in serum, to measure the effect on non-specific protein binding; transchelation, to 




simulate the low concentration of radiolabelled complexes in vivo; and transmetallation, to 
observe the effect of biologically relevant metals at higher concentrations. In some studies, 
transmetallation has focussed on a wide array of biologically relevant metal ions.64 However, 
evidence from these studies has suggested that only Fe(III) causes significant demetallation of 
89Zr-DFO. While Al(III) displays a high affinity for DFO, it is less concentration in biological 
systems compared to Fe(III). As discussed earlier, the high binding constant between DFO and 
Fe3+ suggests that trivalent cations would provide the greatest competition for zirconium-8926, and 
thus Fe(III) was the sole focus of our transmetallation experiments. Bovine serum albumin (BSA) 
is used to assess the effects of non-specific protein binding, while incubation with high 
concentrations of EDTA at biologically relevant pH can be used to assess transchelation. 
 
Radio-TLC provides a simple and robust method by which to deduce the radiochemical stability 
of complexes.64 This process involves the use of a trans-chelating agent at a high concentration 
in the mobile phase to separate unbound radioisotopes in solution from those already chelated; 
the TLC plates are then halved and examined to determine the ratio between the stationary 
(chelated) and mobile (unbound) components. Preliminary experiments were performed to 
confirm the TLC elution solvent; 0.1 M sodium citrate, 0.1 M ammonium acetate, and 0.1 M EDTA 
were used to compare radiolabelled 89Zr-DFO and free 89Zr4+. 0.1 M EDTA was selected as the 
elution solvent as it resulted in consistent movement of free 89Zr4+, while 89Zr-DFO was retained 
at the baseline.  
  





Table 4: Initial radiochemical yield for compound 8.1, DFO, DOTA and DOTA-TATE labelled with 89Zr over 
2 h at 37° C (compound 8.1, DFO) or 90° C (DOTA, DOTA-TATE), including total gamma counts for each 
sample.  
Time (mins)  30 60 120 
8.1 Yield 84% 88% 86% 
 Counts 152471 163132 147255 
DFO Yield 99%  91% 
 Counts 232764  174141 
DOTA Yield 8.2% 7.8% 7.1% 
 Counts 148412 172495 164025 
DOTA-
TATE 
Yield 71% 70% 72% 
 Counts 110159 101610 81458 
 
A total of 9.79 MBq of 89Zr(ox)2 was diluted to a volume of 400 μL with water; even aliquots of 100 
μL of this solution were added to prepared solutions of 200 μL DMSO, 10 μg of the respective 
chelator (compound 8.1, DFO, DOTA and DOTA-TATE), and 690 μL water. The solutions 
containing DOTA and DOTA-TATE were incubated at 90 °C for 45 minutes as per Pandya et al.,73 
then incubated at 37 °C for 75 minutes. while those containing DFO and compound 8.1 were 
incubated at 37 °C for 120 minutes. Radiochemical yields (the proportion of chelated to free 
radiometals) were assessed by radio-TLC and a gamma counter at 30, 60 and 120 minutes. The 
radiochemical yield can be assessed by comparing the quantity of radioactive emissions from the 
solvent front of each TLC plate to those on the baseline, as chelated 89Zr does not migrate with 
the solvent front.  
Analysis by radio-TLC at 30 minutes indicated that the solution containing DFO exhibited 
markedly higher gamma counts than the other solutions. As free 89Zr4+ would migrate with the 
solvent front, it is possible that precipitation of 89Zr4+ or 89Zr-chelator complexes in the other 
solutions caused this effect. 100 μL aliquots of methanol were added to each solution at 30 
minutes, with radiochemical yields also measured at 60 and 120 minutes. The results of 
radiolabelling are shown in Table 4. This led to increased radioactivity counts in the solutions 
containing compound 8.1 and DOTA, but not for that containing DOTA-TATE. Both DOTA and 




DOTA-TATE were excluded from the following challenge assay due to the low radiolabelling yield 
of the former, and apparent low solubility of the latter. The results of these initial radiolabelling 
experiments indicated that both DFO and 8.1 formed complexes with 89Zr, while DOTA did not. 
Challenge assays were performed on compound 8.1 and DFO as outlined below.64 The results 
are summarised in Table 5, while more detailed discussions of each experiment are addressed 
below. Stability is presented as average total gamma counts and the proportion of 
complexed/uncomplexed 89Zr, with calculated standard errors. Total gamma counts are only of 
limited use in interpreting these experiments; while they highlight some consistent differences 
between the solutions containing 8.1 and DFO, total counts can fluctuate significantly between 
TLC experiments, as they depend on the volume of radiolabelling solution applied to the TLC 
plate. 
Table 5: Summary of radiochemical stability experiments 3.1.2-3.1.4. Radiochemical stability of 89Zr-8.1 
and 89Zr-DFO during incubation in challenge assays over 7 days at 37° C. Experiments were performed 
in triplicate for each group. Initial (t=0) measurements taken from radiolabelling experiment 3.1.1. 
  % stability after incubation time 
Time (h) 0 24 72 96 120 168 
 8.1 DFO 8.1 DFO 8.1 DFO 8.1 DFO 8.1 DFO 8.1 DFO 
Fe(III) 86 91 68 ± 2.2 99 ± 0.0 42 ± 5.3 99 ± 0.2 37 ± 3.9 96 ± 0.7 26 ± 4.2  97 ± 1.0 38 ± 6.9 96 ± 1.0 
BSA 86 91 71 ± 0.6 92 ± 0.7 46 ± 1.9 91 ± 0.7 57 ± 1.6 86 ± 0.2 47 ± 3.0 85 ± 2.1 60 ± 2.2 89 ± 1.6 
pH 7.4 86 91 97 ± 1.0 99 ± 0.0 87 ± 3.4 97 ± 0.4 82 ± 1.7 91 ± 2.5 83 ± 0.4 87 ± 5.7 84 ± 2.9 95 ± 0.4 
pH 5 86 91 95 ± 2.0 98 ± 0.9 91 ± 2.3 96 ± 0.6 17 ± 3.3 73 ± 11 9.0 ± 2.6 66 ± 17 24 ± 8.0 65 ± 15 
 
3.1.2 Fe(III) Challenge assay 
Table 6: Radiochemical stability and average total gamma counts for 89Zr-8.1 and 89Zr-DFO, incubated for 
7 days at 37 °C in 10-fold Fe(III). Initial (t=0) measurements taken from radiolabelling experiment 3.1.1. 
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Aliquots of 50 μL of the prelabelled 89Zr-chelator solutions were added to solutions of 50 μL FeCl3 
solution (1 μM) and 300 μL PBS. The resultant solutions were incubated for 7 days at 37 °C, with 
stability assessed by radio-TLC at regular intervals, as seen in Table 6. 
 
The 89Zr-8.1 complex underwent significant demetallation over 7 days in the presence of Fe(III), 
while the 89Zr-DFO complex maintained stability of over 95%. The stability of the 89Zr-DFO 
complex is higher than reported,64 with close clustering of results. Meanwhile, the reduced 
stability of the 89Zr-8.1 complex is somewhat expected due to the decreased denticity of 
compound 8.1 compared to DFO. Of note is the marked reduction in total average gamma counts 
observed in samples containing the 89Zr-8.1 complex compared to those containing 89Zr-DFO; as 
in the radiolabelling experiment, it is postulated that insolubility contributed to this difference, as 
the challenge assays contained a reduced percentage of organic solvents. It is unknown whether 
the insoluble components remained chelated or as precipitated metal salts, such as the insoluble 
89Zr(OH)4. 
3.1.3 BSA challenge assay 
Table 7: Radiochemical stability and average total gamma counts for 89Zr-8.1 and 89Zr-DFO, incubated for 
7 days at 37 °C in 1% BSA solution. Initial (t=0) measurements taken from radiolabelling experiment 3.1.1. 
Time (h) 0 24 72 96 120 168 
 8.1 DFO 8.1 DFO 8.1 DFO 8.1 DFO 8.1 DFO 8.1 DFO 
% stability 86 91 71 ± 0.6 92 ± 0.7 46 ± 1.9 91 ± 0.7 57 ± 1.6 86 ± 0.2 47 ± 3.0 85 ± 2.1 60 ± 2.2 89 ± 1.6 
Avg. total 
counts 
7363 8707 3981 4350 4223 5789 4210 4138 2241 2235 1914 2086 
 
Aliquots of 50 μL of the prelabelled 89Zr-chelator solutions were added to solutions of 450 μL of 
1% bovine serum albumin and incubated at 37° C for 7 days, in order to test the effects of non-
specific protein binding of the 89Zr-chelator complexes. The resultant radiochemical stability was 
assessed by radio-TLC at regular intervals; these data are shown above in Table 7.  
 




The 89Zr-8.1 complex underwent demetallation over 7 days, with a marked reduction in metal 
binding observed even after 24 hours. Conversely, the 89Zr-DFO complex underwent slow 
demetallation, remaining above 85% stable after 1 week, representing a substantially lower 
stability than previously reported.64 The difference in total average gamma counts between 
solutions containing 8.1 and DFO was much less significant in this assay.  
3.1.4 EDTA challenge assays 
Table 8: Radiochemical stability and average total gamma counts for Zr-8.1 and Zr-DFO, incubated for 7 
days at 37 °C in 100-fold EDTA at pH 7.4 or pH 5. . Initial (t=0) measurements taken from radiolabelling 
experiment 3.1.1. 
 Time (h) 0 24 72 96 120 168 
  8.1 DFO 8.1 DFO 8.1 DFO 8.1 DFO 8.1 DFO 8.1 DFO 
pH 
7.4 






















14726 17414 9199 17945 11203 23609 12454 23957 6169 16499 3936 8437 
pH 
5.0 










73 ± 11 9.0 ± 
2.6 
66 ± 17 24 ± 
8.0 
65 ± 15 
 Avg. tot. 
counts 
14726 17414 9714 17377 12317 28665 17432 18396 10190 13227 7044 8708 
 
Aliquots of 100 μL of the prelabelled 89Zr-chelator solutions were added to solutions containing 
100 μL of 10 μM EDTA solution (approximately 100-fold) and 50 μL of PBS to assess the effects 
of transchelation at biologically relevant pH. One solution was maintained at pH 7.4 while the 
other was reduced to pH 5 by the addition of 0.05 mM HCl. These solutions were incubated at 
37° C for 7 days and radiochemical stability was assessed at regular intervals by radio-TLC; 
these data are shown in Table 7. After 72 hours the pH of each solution was tested and corrected 
accordingly by the addition of 0.05 mM HCl. 
 
At pH 7.4, both the 89Zr-8.1 complex and the 89Zr-DFO complex exhibited good stability, with 84% 
and 95% of the complexes remaining intact after 7 days respectively. The result for the 89Zr-DFO 
complex was comparable to the reported data.64 The stability exhibited by the 89Zr-8.1 complex 
was remarkably comparable in these conditions.  





Meanwhile, at ph 5, the 89Zr-8.1 complex was significantly demetallated after 7 days, while 89Zr-
DFO complex displayed some demetallation, reporting 24% and 65% stability respectively. 
Statistical error was significant particularly in the 89Zr-DFO group, due in part to one sample 
containing 89Zr-DFO which remained 93% stable after 7 days. Under both sets of conditions, the 
observed total counts for the 89Zr-DFO group was significantly greater than for the 89Zr-8.1 group, 
indicating possible solubility issues. Interestingly, with the majority of the 89Zr-8.1 demetallated in 
pH 5 after 7 days, the differences in total counts between groups were less marked.  
3.2 Gallium-68 stability studies 
As previously mentioned, DFO shows affinity for Ga3+ ions and radiolabelling occurs quickly; 
however, 68Ga-DFO complexes are unstable, vulnerable to transchelation and competitive metal 
ions (particularly Fe(III)).28-30 The ease of production of 68Ga made the radiochemical assessment 
of the 68Ga-8.1 complex of interest.  
 
68Ga was eluted from a 68Ge/68Ga generator with 0.1 M hydrochloric acid as per the reported 
method.30 An aliquot of 50 μL of this solution was combined with 10 μL of selected chelators 
(DFO-B and compound 8.1) and 40 μL of sodium acetate solution (0.5 M) to form standard 
solutions. The solutions were incubated at 37 °C for 30 minutes and binding assessed by radio-
TLC; 100 μL of sodium acetate solution (0.5 M) was then added to increase the pH, and 20 μL of 
methanol and 10 μL of DMSO were added to both solutions.  
 
Of these solutions, 10 μL aliquots were taken and combined with 90 μL of either 3% BSA solution 
or 0.1M FeCl3 solution. All solutions were incubated at 37 °C for a total of 120 minutes. Binding 
proportion was assessed at regular intervals by radio-TLC and a gamma counter. Due to the low 
half-life of 68Ga and the low radioactivity of each sample, radioactivity levels in some later samples 




were too insignificant to be detected above background levels. The stability values are presented 
below in Table 9. 
Table 9: Radiochemical stability of 68Ga-chelator complexes over 2 hours as percentage bound 68Ga. 
Time (mins) 30 60 120 
 DFO 8.1 DFO 8.1 DFO 8.1 
Standard 74 ± 17 53 ± 21 97 ± 0.4 35 ± 12 97 ± 0.5 15 ± 6.3 
Fe3+ 17 ± 9 10 ± 4.1 9.1 ± 1.4 5.5 ± 2.2 7.6 ± 6.3 - 
BSA 78 ± 20 62 ± 18 7.3 ± 1.4 36 ± 29 28 ± 13 40 
 
As apparent in Table 9, in the standard solutions the 68Ga-DFO complex was particularly stable, 
recording 97% stability after 2 hours; meanwhile the 68Ga-8.1 complex was only partly formed 
and its stability deteriorated to 15% after 2 hours. The poor performance of compound 8.1 in this 
assay demonstrated its unsuitability for use with 68Ga. 
 
In the presence of Fe3+ ions, both the 68Ga-DFO complex and 68Ga-8.1 complex were shown to 
be highly unstable, undergoing rapid demetallation after the first 30 minutes. The data observed 
for the 68Ga-DFO complex showed decreased stability compared to reported data.29 There was 
insufficient radiation after 2 hours in samples of the 68Ga-8.1 complex; however extensive 
demetallation of this complex had already occurred after 1 hour. 
 
Both complexes displayed poor stability in solutions containing 3% BSA; an average of only 28% 
of the 68Ga-DFO complex remained intact, while the sole sample of the 68Ga-8.1 complex 
containing measurable quantities of radiation remained 40% intact. As this sample was an outlier 
during the 30- and 60-minute measurements, this data is unlikely to be accurate. The results 
observed for 68Ga-DFO were again markedly lower than previously reported.29  
 
The above data does not suggest either chelator is suitable for therapeutic use with 68Ga. 
 












4 Conclusions and future directions 
 
The above work has uncovered some new information with regards to the syntheses of 
hydroxamate-based chelators. Through the attempted syntheses of compounds 8 and 10, it was 
demonstrated that chelators containing α-amino acids are susceptible to intramolecular 
degradation. Previous works on similar molecules had hinted at such an effect without further 
examination.68 This degradation ultimately led to the synthesis of the tripeptide, 
monohydroxamate compound 8.1. It is likely that the basicity of the peptide coupling reactions 
combined with lengthy reaction times amplified this degradation. Other previously unreported 
instabilities were observed under basic conditions, particularly during attempted deesterification, 
further hindering synthesis. 
 
Meanwhile, compound 14 was successfully synthesised by solid-phase peptide synthesis with no 
signs of intramolecular degradation. While only 10 mg of the chelator was synthesised, only low 
quantities are required for use as radiotherapeutics. This synthesis verified the potential of SPPS 
in forming these compounds, while also giving credence to the hypothesis that α-amino acids are 
the origin of instability in compounds such as 8. 
  
Radiochemical assessment was undertaken on compound 8.1 to determine its binding affinities 
for zirconium-89 and gallium-68 compared to DFO. While 8.1 was outperformed by DFO in both 
functions as expected, it showed surprising radiochemical stability as a zirconium-89 chelator, 
with good resistance to EDTA observed at neutral pH. Given the low stability of monohydroxamate 
units in conjunction with zirconium-89,23 this suggests that complexation is occurring between 
other groups of 8.1 and zirconium-89.  
 




Ultimately, these observations affirm the superior stability of zirconium-89 chelators containing β-
amino acids. However, it also gives basis for the future syntheses of chelators 8 and 10: the 
addition of HOBt has been shown to reduce the formation of aspartimide-like side products during 
SPPS,91 and the reduced reaction time required for SPPS could help reduce the formation of 
side-products. While the use of SPPS results in low yields, it could be useful to synthesise linear 
chelators such as 8 and 10. Further work would naturally also include the substitution of other α-
amino acids into these chelators to create a more diverse library of compounds.  
 
  










5 Appendices  
5.1 Experimental 
5.1.1 Materials 
All reagents were obtained from Chem-Impex international unless specified below. Ethyl acetate, 
methanol, dichloromethane, lithium hydroxide, and N-N-dimethylformamide were obtained from 
Merck. Isopropanol, acetone, acetic acid, hydrochloric acid, sodium sulfate and toluene from 
Chemsupply; chloroform and tetrahydrofuran from RCI Labscan, and HPLC-grade methanol and 
acetone from Ajax Finechem. Benzyloxy(tert-butoxycarbonyl)amine, ethyl 7-bromo heptanoate, 
N-N-diisopropylamine, DFO-B, sodium hydride, EDTA, BSA and trifluoroacetic acid were obtained 
from Sigma Aldrich. HEPES, PBS and sodium acetate were obtained from Gibco. TraceSelect™ 
water was obtained from Honeywell.  
All commercially purchased reagents were used without further purification. 
5.1.2 Analysis 
5.1.2.1 Analytical Methods 
Analysis by TLC was performed on TLC Silica gel 60 F254 obtained from Merck, eluting with ethyl 
acetate/hexane or methanol/DCM as specified. TLC plates were observed under UV radiation at 
254nm and staining was performed with 6% w/v vanillin in EtOH, CAM solution or KMnO4 solution. 
Purity of products was assessed by reverse-phase HPLC using a Phenomenex Luna C18(2) 
column over a gradient of 50-95% aq. ACN over 15 minutes unless otherwise stated. Product 
formulae were confirmed by HRMS on an Agilent 6230 ESI-TOF LCMS, and low-resolution mass 
spectrometry was performed with an Agilent 1260 Infinity LCMS.  
  




5.1.2.2 NMR Spectroscopy 
All NMR spectra were acquired using an Agilent spectrometer (Agilent DD2 Console) in 100% 
CDCl3, 100% DMSO-D6, or 100% CD3OD at 298° K. 1HNMR were obtained at 500 MHz and 
13CNMR were obtained at 125 MHz. Chemical shifts are reported in ppm based on 
tetramethylsilane. 
5.1.2.3 Purification 
Normal phase column chromatography was performed with silica gel 60 obtained from Carl Roth 
Gmbh, while reverse phase column chromatography was performed on 60A C18 gel obtained from 
Silicycle; flash chromatography was performed under positive pressure from nitrogen gas. 
Purification by HPLC was undertaken with Gilson Semi-preparatory RP-HPLC using a Supelco 
Discovery BIO Wide Pore C18 column over 45-60% aq. ACN over 20 minutes. 
5.1.2.4 Radio-TLC experiments 
Radioligand stability was determined by elution on iTLC-SG chromatography paper (obtained 
from Agilent) in 0.1M EDTA solution; measurement of emissions occurred by HIDEX Multi-
Channel Analyser and Scanram TLC/HPLC Analyser. 68Ga was produced by an Eckert & Ziegler 
Model IGG100 68Ge/68Ga generator. 
Zirconium-89 was produced as per Holland et al. A 99.9% pure 89Y foil target (0.15 x 0.25 mm, 
99.9% pure), purchased from American Elements, was bombarded with a proton beam of 16.9 
MeV and 30 μA for 300 minutes on a GE PETtrace 880 cyclotron with a Comecer Taddeo 
purification system.16 The target was dissolved in 6 M hydrochloric acid; the solution was diluted 
with water to reach a concentration of 2M. The zirconium-89-containing solution was then purified 
by an automatic cassette. The zirconium-89-containing solution was placed into a column 
containing hydroxamate resin and washed with 2 M hydrochloric acid (x4, 2.5 mL) to remove 
excess Y3+. Zirconium-89 was removed from the column by addition of 1.0 M oxalic acid.   






1. Ethyl 7-((benzyloxy)(tert-butoxycarbonyl)amino)heptanoate 
To a solution of tert-butyl N-(benzyloxy)carbamate (0.447 g, 2.0 mmol) in DMF (5 mL) was added 
60% NaH in mineral oil (0.088 g, 2.2 mmol) and the mixture was stirred for 15 minutes on ice. To 
the mixture was added ethyl 7-bromo heptanoate (0.593 g, 0.49 mL, 2.5 mmol) dropwise, and 
the resulting solution was stirred for 20 hours at RT. H2O (20 mL) was added and the solution 
was extracted with ethyl acetate (3 x 10 mL). The organic eluents were combined and washed 
with saturated sodium chloride solution (3 x 20 mL). The organic solvent was removed under 
reduced pressure yielding a crude product of mass of 0.650 g. The crude product was purified by 
column chromatography using 1:4 ethyl acetate:hexane to yield a clear gum (0.524 g, 69%).  
 
To a solution of tert-butyl N-(benzyloxy)carbamate (3.350 g, 15 mmol) in DMF (75 mL) was added 
60% NaH in mineral oil (0.600 g, 15 mmol) and the mixture was stirred for 30 minutes on ice. To 
the mixture was added ethyl 7-bromo heptanoate (4.450 g, 3.70 mL, 19 mmol) dropwise, and the 
resulting solution was stirred for 20 hours at 60°C. The solvent was removed under reduced 
pressure and the products dissolved in ethyl acetate (50 mL) and washed with water (3 x 50 mL) 
and saturated sodium chloride solution (2 x 50 mL). The organic layer was dried with Na2SO4 and 
removed under reduced pressure to yield a crude oil of mass 5.513 g. The crude product was 
purified by column chromatography using 1:9 acetone:hexane to yield (1) as a clear oil (3.672 g, 
64%).  
 
1HNMR (CDCl3 500 MHz) δ 7.33 – 7.41 (5H, m); 4.82 (2H, s); 4.12 (2H, q); 3.40 (2H, t); 2.28 (2H, 
t); 1.57 – 1.64 (4H, m); 1.51 (9H, s); 1.28 - 1.35 (4H, m); 1.25 (3H, t). 




13CNMR (CDCl3 125 MHz) δ 176.38, 159.25, 138.37, 131.05, 83.77, 62.81, 52.21, 36.93, 31.47, 
31.00, 29.55, 29.08, 27.52, 16.90.  
HRMS: m/z = 379.24 [M + H] 380.2429, [M + Na+] 402.2260.  
HPLC: 21.89 mins. 
  





3. Ethyl 7-(N-(benzyloxy)-2-((tert-butoxycarbonyl)amino)acetamido)heptanoate 
Ethyl 7-((benzyloxy)(tert-butoxycarbonyl)amino)heptanoate (1) (1.840 g, 4.8 mmol) was 
dissolved in dichloromethane (4 mL) and to this was added TFA (1 mL). The resultant solution 
was stirred for 2 h at RT. The solvent was removed under nitrogen gas and then under reduced 
pressure to give ethyl 7-((benzyloxy)amino)heptanoate (2) as a brown gum (1.345 g, 100%).  
 
1HNMR (CDCl3 500 MHz) δ 10.54 (4H, ws), 7.35 – 7.45 (5H, m), 5.10 (2H, s), 4.15 (2H, q) 3.31 
(2H, t), 2.31 (2H, t), 1.76 (2H, quint.), 1.61 (2H, quint.), 1.35 (4H, m), 1.26 (3H, t).  
LRMS: m/z = 279.18, [M + H] 280.2. 
HPLC: 5.88 mins 
 
To a sample of Ethyl 7-((benzyloxy)amino)heptanoate (2) (1.345 g, 4.8 mmol) was added a 
solution of Boc-glycine (1.019 g, 5.8 mmol), HATU (2.212 g, 5.8 mmol) and DIPEA (3.80 mL, 22 
mmol) in DMF (15 mL). The resultant solution was stirred for 16 hours at room temperature and 
monitored by TLC. The solution was neutralised with NaHCO3 (20 mL) and extracted with ethyl 
acetate (3 x 20 mL). The organic extracts were combined and washed with H2O (3 x 20 mL) and 
brine (5 x 20mL), dried with Na2SO4 and the solvent removed under reduced pressure to yield a 
brown oil (2.409 g, crude). This oil was purified by column chromatography using 0:1 → 3:7 
EtOAc:hexane to yield Ethyl 7-(N-(benzyloxy)-2-((tert-
butoxycarbonyl)amino)acetamido)heptanoate (3) as a yellow oil (1.790 g, 70%).  
 
1HNMR (CD3OD 500 MHz) δ 7.42 (5H, m), 4.93 (2H, s), 4.11 (2H, q), 3.97 (2H, s), 3.67 (2H, t), 
2.29 (2H, t), 1.55 – 1.70 (4H, m), 1.46 (9H, s), 1.33 (4H, m), 1.24 (3H, t). 




13CNMR (CD3OD 125 MHz) δ 176.76, 159.80, 137.27, 131.84, 131.30, 131.00, 78.68, 62.62, 
43.97, 36.22, 30.91, 29.97, 28.53, 27.11, 15.80.  
HRMS: m/z = 436.26 [M+H]; 475.22 [M+K]. [M+H] = 437.2633, [M+K+] = 475.2192. 
HPLC: 17.41 mins.  





3.1.  Ethyl 7-(N-(benzyloxy)-2-((fluorenylmethyloxycarbonyl)amino)acetamido)heptanoate 
To a sample of Ethyl 7-((benzyloxy)amino)heptanoate (2) (0.139 g, 0.5 mmol) was added a 
solution of Fmoc-glycine (0.156 g, 0.5 mmol), HATU (0.224 g, 0.6 mmol) and DIPEA (0.340 mL, 
2.0 mmol) in DMF (4 mL). The resultant solution was stirred for 16 hours at room temperature 
and monitored by TLC. The solution was neutralised with NaHCO3 (20 mL) and extracted with 
ethyl acetate (3 x 20 mL). The organic extracts were combined and washed with H2O (3 x 20 mL) 
and brine (5 x 20mL), dried with Na2SO4 and the solvent removed under reduced pressure to 
yield a brown oil (0.252 g, crude). This oil was purified by column chromatography using 0:1 → 
3:7 ethyl acetate/hexane to yield the intermediate ethyl 7-(N-(benzyloxy)-2-
((fluorenylmethyloxycarbonyl)amino)acetamido)heptanoate (3.1) as a yellow oil (0.194 g, 69%).  
 
1HNMR (CDCl3 500 MHz) δ 7.77 (2H, d), 7.62 (2H, d), 7.29 – 7.46 (9H, m), 4.87 (2H, s), 4.39 (2H, 
d), 4.26 (1H, t), 4.10 – 4.18 (4H, m), 3.67 (2H, t), 2.29 (2H, t), 1.58 – 1.71 (4H, m), 1.29 – 1.40 
(4H, m), 1.26 (3H, t).  





4a. Ethyl 7-(N-(benzyloxy)-2-((tert-butoxycarbonyl)amino)acetamido)heptanoic acid 
A sample of Ethyl 7-(N-(benzyloxy)-2-((tert-butoxycarbonyl)amino)acetamido)-heptanoate (3) 
(0.370 g, 0.8 mmol) was dissolved in THF (5 mL) and cooled on ice. To this was added 1M LiOH 
solution (5.10 mL). The reaction was stirred on ice for 15 minutes, then stirred at room 
temperature for a further 20 h. The solution was neutralised by the addition of 2M HCl (3 mL) and 
was extracted with ethyl acetate (3 x 20 mL); the organic eluents were dried with Na2SO4 and 
removed under reduced pressure to yield a clear oil (0.234 g, crude). The crude product was 
purified by column chromatography using 1:1 EtOAc/hexane with 1% AcOH to yield 4a as a yellow 
oil (0.079 g, 23%).  
 
1HNMR (CDCl3 500 MHz) δ 7.39 (5H, s), 4.84 (2H, s), 4.08 (2H, s), 3.64 (2H, s), 2.33 (2H, t), 1.63 
(4H, m), 1.46 (9H, s), 1.33 (4H, m). 
13CNMR (CD3OD 125 MHz) δ 131.84, 131.30, 131.00, 81.82, 78.69, 43.97, 36.07, 30.98, 29.97, 
28.78, 28.59, 27.15.  
HPLC: 18.236 min (10-100% MeOH over 15 minutes). 
  





4c. Ethyl 7-(N-(benzyloxy)-2-((fluorenylmethyloxycarbonyl)amino)acetamido) 
heptanoic acid 
 Attempted 
 Fmoc-Gly-ethyl heptanoate (0.046 g, 0.083 mmol) was dissolved in anhydrous THF (2 mL) and 
combined with MgI2 (0.115 g, 0.41 mmol). The resultant mixture was heated to 120°C by 
microwave radiation for 2 hours. The solution was neutralised by addition of 0.1M sodium 
thiosulfate solution (2 mL); analysis by 1HNMR found that compound 4c was not successfully 
produced. 
 
Fmoc-Gly-ethyl heptanoate (0.030 g, 0.054 mmol) was dissolved in IPA (3.5 mL); to this was 
added a solution of LiOH (0.005 g, 0.22 mmol) in H2O (1.5 mL). To this overall solution was added 
CaCl2 (0.278 g, 2.5 mmol) to bring the solution to a concentration of 0.5M. This reaction was 
stirred for 21 h and monitored by TLC, then neutralised by addition of 1M HCl (1 mL). The solution 
was extracted with EtOAc (3 x 20 mL) and the organic eluents were washed with brine (3 x 20 
mL) and dried with Na2SO4. Analysis of the crude organic extracts by 1HNMR showed the reaction 
had not progressed. 
  





5. Ethyl 7-(N-(benzyloxy)-2-((tert-butoxycarbonyl)amino)acetamido)heptanoate  
To compound 3 (0.280 g, 0.6 mmol) was added a solution of 20% TFA in DCM (10 mL) and the 
resultant solution was stirred for 2 hours. The progress of the reaction was monitored by TLC. 
The TFA/DCM solution was subsequently removed by nitrogen gas and under reduced pressure, 
yielding compound 4b as a brown oil (0.216 g, 100%).  
 
1HNMR (CDCl3 500 MHz) δ 7.37 (5H, d), 4.82 (2H, s), 4.10 (2H, q), 3.88 (2H, s), 3.63 (2H, s), 
2.27 (2H, t), 1.57 (4H, m), 1.26 (7H, m). 
HPLC: 5.59 mins. 
 
To a sample of 4b (0.216 g, 0.6 mmol) was added a solution of compound 4a (0.270 g, 0.7 mmol), 
HATU (0.302 g, 0.8 mmol) and DIPEA (0.6 mL, 3.4 mmol) in DMF (4 mL); further DIPEA (0.5 mL, 
2.9 mmol) was added to quench residual TFA and increase the solution pH. The solution was 
stirred for 48 hours and the progress monitored by TLC; at the 24-hour mark, more HATU (0.1 g, 
0.2 mmol) and DMF (2.0 mL) was added. The reaction was quenched with sodium hydrogen 
carbonate (30 mL) and extracted with ethyl acetate (3 x 20 mL). The organic eluents were 
combined and washed with water (20 mL) and saturated sodium chloride solution (5 x 20 mL); 
following this they were dried with sodium sulfate and the solvent was removed under reduced 
pressure to yield a yellow oil (0.320 g, crude). This was purified by flash chromatography (1:1 
ethyl acetate/hexane) to yield compound 5 as a clear oil (m = 0.028 g). The remaining crude 
solution was purified again by flash chromatography (7:3 ethyl acetate/hexane) yielding 
compound 5 as a clear oil (0.072 g), and both eluents were combined (0.100 g, 21%).  
 




1HNMR (CD3OD 500 MHz) δ 7.38 – 7.46 (10H, m), 4.82 (4H, s), 4.10 (2H, q), 4.09 (2H, S), 3.98 
(2H, s), 3.67 (4H, d), 2.29 (2H, t), 1.51 – 1.69 (8H, m), 1.46 (9H, s), 1.26 – 1.40 (8H, m), 1.24 (3H, 
t). 
13CNMR (CD3OD 125 MHz) δ 177.85, 176.70, 171.41, 159.76, 137.28, 131.90, 131.86, 131.33, 
131.02, 130.71, 130.40, 130.17, 81.79, 78.67, 62.63, 47.78, 44.02, 42.87, 41.58, 37.99, 37.95, 
36.24, 31.35, 31.04, 30.96, 30.93, 30.02, 29.92, 28.78, 28.60, 28.56, 27.96, 27.88, 27.12, 15.86.  
HRMS: m/z = 726.42 [M+H], 749.41 [M+Na]; [M+H] = 727.4280, [M+Na] = 749.4098.  
HPLC: 18.15 mins   






Compound 5 (0.080 g, 0.1 mmol) was dissolved in THF (0.7 mL) and cooled on ice. To this 
solution was added 1M LiOH solution (0.66 mL) and the resultant solution was stirred for 12 hours. 
The excess LiOH was neutralised and the solution acidified by addition of HCl (1 mL) and H2O 
(10 mL), before extraction with ethyl acetate (3 x 20 mL). The organic eluents were dried with 
Na2SO4 and the solvent removed under reduced pressure to yield a clear oil (0.065 g, crude). 
The crude product was unable to be purified by column chromatography using 1:24 MeOH/DCM, 
with the reaction yielding a mixture of by-products. 
  





6b. To a solution of compound 5 (0.075 g, 0.1 mmol) in DCM (6 mL) was added TFA (1.5 mL) and 
the solution was stirred for 2 hours. The TFA was removed by nitrogen gas and under reduced 
pressure yielding 6b as a brown oil (0.076 g, 100%).  
 
1H NMR (CD3OD 500 MHz) δ 7.42 (10H, m), 4.94 (4H, s), 4.13 (6H, m), 3.75 (3H, s), 3.69 (3H, 
m), 2.29 (4H, t), 1.62 (8H, m), 1.32 (8H, m), 1.23 (3H, t). 
13CNMR (CD3OD 125 MHz) δ 176.82, 169.16, 162.13, 161.82, 161.51, 161.20, 137.17, 132.53, 
132.07, 131.91, 131.88, 131.40, 131.34, 131.16, 131.05, 131.03, 119.25, 116.96, 78.67, 62.66, 
50.79, 50.62, 50.56, 50.45, 50.28, 50.11, 49.94, 49.77, 43.00, 42.87, 42.78, 40.16, 37.92, 36.23, 
34.30, 33.08, 32.17, 32.05, 31.98, 31.70, 31.35, 31.00, 30.91, 30.90, 28.71, 28.54, 28.51, 27.93, 
27.84, 27.09, 24.97, 15.79, 15.69.  
HPLC: 5.39 mins. 
  





7. Compound 4a (0.079 g, 0.2 mmol) was combined with HATU (0.110 g, 0.3 mmol), DIPEA 
(0.17 mL, 1.0 mmol) and DMF (2 mL) and mixed vigorously for 2 minutes. To this solution was 
then added compound 6b (0.076 g) in DMF (2 mL) and the resultant solution was stirred at room 
temperature for 40 hours. At the 24-hour mark, HATU (0.040 g, 0.1 mmol) and DIPEA (0.04 mL, 
0.2 mmol) were added to the reaction mixture based on analysis by TLC. The solution was 
neutralised by addition of NaHCO3 (5 mL) and H2O (10 mL) and extracted with ethyl acetate (3 x 
20 mL); the organic extracts were combined, washed with brine (5 x 20 mL) and dried with Na2SO4. 
The solvent was removed in vacuo to yield a clear oil (0.114 g, crude). Flash chromatography 
was performed using 1:24 MeOH/DCM to give a mixture of 7, 7.1 and 7.2 based on HRMS (0.066 
g).  
HRMS: m/z: 1016.58; [M+H] 1017.6085, 784.4766, 551.3237.  
1HNMR (CD3OD 500 MHz) of mixture δ 7.45 - 7.40 (m), 4.95 (s), 4.05 – 4.17 (m), 3.94 (s), 3.75 
(s), 3.68 (t), 2.29 (t), 1.55 – 1.70 (m), 1.46 (s), 1.31 – 1.40 (m), 1.23 (t). 
13CNMR (CD3OD 125 MHz) of mixture δ 176.73, 174.34, 131.89, 131.35, 131.02, 78.70, 62.63, 
46.16, 44.62, 42.85, 36.23, 30.91, 29.98, 28.74, 28.53, 27.09, 15.81.  
HPLC: 11.16 mins. 





8.1. The mixture containing compounds 7, 7.1 and 7.2 (0.032 g) was dissolved in ethyl 
acetate (1 mL) and was stirred under a nitrogenous atmosphere. To this was added Pd/C (60% 
w/w, 0.020 g) in ethyl acetate (2 mL) and air was again evacuated from the reaction vessel by 
nitrogen gas. The atmosphere was saturated with H2 at 1atm and the solution was stirred 
overnight. To this solution was added TraceSelect™ water (1 mL) and the solution was filtered. 
The solvent was removed under reduced pressure to yield 8.1 as a clear gum (m = 0.025 g, 
100%). 
1HNMR (DMSO 500 MHz) δ 8.01 (1H, t), 7.86 (1H, t), 6.97 (1H, t), 4.04 (2H, q), 3.98 (2H, d), 3.74 
(2H, d), 3.57 (2H, d), 3.45 (2H, t), 2.26 (2H, t), 2.07 (s, acetonitrile), 1.42 – 1.55 (5H, m), 1.38 (9H, 
s), 1.19 – 1.31 (10H, m), 1.17 (3H, t), 0.85 (1H, t). 
13C NMR (DMSO 125 MHz) δ 175.98, 172.73, 172.14, 171.65, 121.16, 81.23, 62.76, 50.57, 46.42, 
45.03, 36.58, 31.32, 31.23, 29.14, 28.84, 27.49, 17.25, 17.05, 4.26. 
MS: m/z = 460.25, 483.24; [M+H] = 461.3 [M+Na] = 483.2442.  
HPLC: 5.66 min. 





12. Compound 1 (1.00 g, 2.6 mmol) was dissolved in acetone (10 mL) to which was added 
32% hydrochloric acid solution (2.9 mL, 30 mmol) and stirred for 16 hours. The solution was 
diluted by the addition of acetone (40 mL) and the solvent removed under reduced pressure to 
yield the deprotected compound 12 as a crude mixture (0.486 g, 68%,). 
1HNMR (CD3OD 500 MHz) δ 7.42 – 7.49 (5H, m), 5.13 (2H, s), 4.12 (0.3 H, q), 3.34 (2H, t), 2.31 
(2H, t), 1.76 (2H, p), 1.63 (2H, p), 1.35 – 1.49 (4H, m), 1.24 (0.6H, t). 
LRMS: m/z = 251.15, [M+H] = 252.1 
 
The crude compound 12 was subsequently dissolved in DMF (5 mL) to which was added a 
precombined mixture of Fmoc-β-Alanine (1.115 g, 3.5 mmol), HATU (1.362 g, 3.6 mmol), and 
DIPEA (3.12 mL, 18 mmol) in DMF (24 mL); the resultant solution was stirred for 16h under inert 
atmosphere and monitored by TLC. The reaction was ended by the removal of solvent under 
reduced pressure and the resultant oil dissolved in ethyl acetate (50 mL); this organic extract was 
washed with saturated ammonium chloride solution (3 x 20 mL) and brine (5 x 20 mL). The 
organic solvent was removed under reduced pressure and the crude orange oil was purified by 
reverse-phase column chromatography (60% ACN/H2O) to yield 13 as an orange oil (0.440 g, 
23%). 
1HNMR (DMSO 500 MHz) δ 7.77 (2H, d), 7.60 (2H, d), 7.28 – 7.42 (9H, m), 4.79 (2H, s), 4.36 
(2H, d), 4.21 (1H, t), 3.67 (2H, t), 3.48 (2H, m), 2.65 (2H, m), 2.33 (2H, t), 1.59 – 1.69 (4H, m), 
1.28 – 1.40 (4H, m). 
13CNMR (CDCl3 125 MHz) δ 146.61, 143.95, 131.88, 131.78, 131.45, 130.34, 129.70, 127.79, 
122.62, 79.93, 79.68, 79.42, 79.02, 69.52, 49.86, 36.21, 35.29, 31.17, 29.20, 28.90, 27.11. 
HRMS: m/z = 544.26, 567.25; [M+H] = 545.2641, [M+Na] = 567.2461. 
 





14. 2-chlorotrityl resin (2.000 g, 1.15 mmol/g) was weighed and swelled in anhydrous DCM 
(15 mL) for 15 minutes. Fmoc-protected-β-alanine (2.3 mmol, 1 eq.) was dissolved in anhydrous 
DCM (15 mL) and DIPEA (2 mL, 11.5 mmol, 5 eq.) The amino acid solution was added to the 
resin and the solution shaken. The mixture was agitated to 2 hours and MeOH (5 mL) was added; 
the resultant solution was further rocked for 30 minutes. The solvent was removed and the resin 
washed with DMF (5 x 10 mL), DCM (2 x 10 mL), DMF (2 x 10 mL) and DCM (5 x 10 mL), with 
the resin then dried by washing with diethyl ether (5 x 10 mL). The remaining solvent was left to 
dry overnight and the loading calculated, yielding a final loading of 0.44 mmol/g. The resin was 
deprotected by addition of a 0.1M solution of HOBt in 20% piperidine/DMF (2 x 5 mL). 
 
Compound 12 (0.163 g, 0.3 mmol) was combined with DMF (10 mL), PyOxim (0.158 g, 0.3 mmol) 
and DIPEA (0.193 mL, 1.5 mmol, 5 eq) and agitated for 10 minutes. This solution was added to 
the resin and incubated for 6 hours with occasional stirring. The solvent was removed, and the 
resin washed with DMF (3 x 10 mL), DCM (3 x 10 mL) and DMF (3 x 10 mL). Coupling completion 
was assessed by the Kaiser test.88 The Fmoc-protecting group was cleaved by by addition of a 
0.1M solution of HOBt in 20% piperidine/DMF (2 x 5 mL); deprotection was again assessed by 
the Kaiser test. This coupling and deprotection procedure was repeated a total of 3 times. 
The resin was cleaved by addition of a solution of 95/2.5/2.5 TFA/TIPS/H2O for 10 minutes and 
the solvent collected and extracted by addition of diethyl ether. The solvent was removed by rotary 
evaporation. The crude compound was purified by semi-preparative HPLC (45:55 → 60:40 
ACN/H2O) and lyophilised to yield compound 14 as a white crystalline solid (0.010 g). 
 
1HNMR (DMSO 500 MHz) δ 7.83 (1H, t), 7.79 (2H, t), 7.76 (2H, bs), 7.33 – 7.46 (15H, m), 4.86 
(2H, s), 4.81 (4H, m), 3.53 – 3.66 (6H, m), 3.17 – 3.26 (6H, m), 2.95 – 3.04 (2H, m), 2.76 – 2.84 




(2H, t), 2.51 – 2.58 (4H, m), 2.35 (2H, t), 2.01 (6H, t), 1.38 – 1.54 (12H, m), 1.22 (16H, s), 1.15 – 
1.22 (12H, m), 0.84 (3H, t). 
13CNMR (DMSO  125 MHz) 176.03, 175.41, 132.78, 132.48, 132.42, 131.80, 131.66, 131.60, 
43.07, 42.90, 42.74, 42.57, 42.40, 42.23, 42.07, 38.33, 38.22, 37.85, 37.68, 37.04, 34.39, 32.12, 
31.90, 31.81, 31.77, 31.67, 31.35, 29.02, 28.27, 28.24, 25.19. 
LRMS: m/z = 1001.58 [M+H] = 1002.8. 
HPLC = 9.6 minutes (45-60% ACN/H2O, 15 min). 
  





5.1.4.1 Zirconium-89 Radiolabelling 
Zirconium oxalate (9.79 MBq) was neutralised with 1M sodium carbonate (100 μL) and the 
solution diluted to 400 μL with water.  
Desferrioxamine-B (1 mg, 1.8 μmol) was dissolved in water (1 mL); 10 μL of this solution was 
combined with DMSO (200 μL), water (690 μL) and the diluted 89Zr(ox)2 solution (100 μL). The 
resultant solution was incubated at 37 °C for 120 minutes. 
Compound 8.1 (1 mg, 2.1 μmol) was dissolved in water (1 mL); 10 μL of this solution was 
combined with DMSO (200 μL), water (690 μL) and the diluted 89Zr(ox)2 solution (100 μL). The 
resultant solution was incubated at 37 °C for 120 minutes. 
DOTA (1 mg, 2.5 μmol) was dissolved in water (1 mL); 10 μL of this solution was combined with 
DMSO (200 μL), water (690 μL) and the diluted 89Zr(ox)2 solution (100 μL). The resultant solution 
was incubated at 90 °C for 45 minutes and at 37 °C for a further 75 minutes. 
DOTA-TATE (1 mg, 0.7 μmol) was dissolved in water (1 mL); 10 μL of this solution was combined 
with DMSO (200 μL), water (690 μL) and the diluted 89Zr(ox)2 solution (100 μL). The resultant 
solution was incubated at 90 °C for 45 minutes and at 37 °C for a further 75 minutes. 
Radiolabelling proportions were assessed by radio-TLC and a gamma counter at 30, 60 and 120 
minutes. 100 μL aliquots of methanol were added to each solution at 30 minutes.  
Radio-TLC involves the spotting of radiochemical solutions onto a paper medium before elution 
with a predetermined solvent (0.1M EDTA solution). After elution, gamma counts are measured 
for the baseline and solvent front and compared to assess the proportion of chelated radiometal. 
The average of total gamma counts and calculated standard errors across each sample are 
presented for each challenge assay. 
 
  




5.1.4.2 Zirconium-89 Challenge Assays 
The radiolabelled chelators were incubated for 7 days in the following solutions: (i) 100-fold EDTA 
at pH 7.4; (ii) 100-fold EDTA at pH 5.0; (iii) in 1% BSA solution; (iv) with 10-fold Fe3+. Triplicate 
solutions were prepared for each set of conditions, with results presented as average proportions 
with calculated standard errors. Radiolabelling proportions were assessed by radio-TLC at 
regular intervals. Elution of TLC was performed in 0.1M EDTA solution. 
 
Fe(III): Aliquots of 50 μL of the prelabelled 89Zr-chelator solutions were added to solutions of 50 
μL FeCl3 solution (1 μM) and 300 μL PBS. The resultant solutions were incubated for 7 days at 
37 °C. 
BSA: Aliquots of 50 μL of the prelabelled 89Zr-chelator solutions were added to solutions of 450 
μL of 1% bovine serum albumin and incubated at 37° C for 7 days.  
EDTA (pH 7.4): Aliquots of 100 μL of the prelabelled 89Zr-chelator solutions were added to 
solutions containing 100 μL of 10 μM EDTA solution (approximately 100-fold) and 50 μL of PBS. 
These solutions were incubated at 37° C for 7 days.  
EDTA (pH 5): Aliquots of 100 μL of the prelabelled 89Zr-chelator solutions were added to solutions 
containing 100 μL of 10 μM EDTA solution (approximately 100-fold) and 50 μL of PBS. These 
solutions were incubated at 37° C for 7 days. To each solution was added 0.05 mM HCl (1 μL) to 
reduce the pH to 5. After 72 hours further 0.05M HCl (1 μL) was added to each solution to maintain 
pH at 5. 
  




5.1.4.3 68Ga radiolabelling 
68GaCl3 (700 μL, 4.79MBq) was eluted from a 68Ge/68Ga generator with 0.1 M HCl. 50 μL aliquots 
of this solution were incubated with 10 μL solutions of the chelators DFO-B (1 μg/μL in H2O) and 
8.1 (1 μg/μL in MeOH) and 0.5M sodium acetate (40 μL) at 37 °C for 30 minutes. To each solution 
was added a further 100 μL of 0.5M sodium acetate. 68Ga-complex formation was measured by 
radio-TLC by elution with 0.1 M citric acid. The solutions were incubated for a further 90 minutes 
with radio-TLC performed at 60 and 120 minutes. 
5.1.4.4 68Ga challenge assay 
10 μL aliquots of the above solutions were combined with 90 μL of either 0.1M FeCl3 solution or 
3% bovine serum albumin solution and incubated at RT for 2 hours, with TLC eluted in 0.1 M citric 
acid solution at 30, 60 and 120 minutes. Stability was determined by radio-TLC.  
  





5.2.1 1-dimensional 1HNMR Spectra 
 
Spectrum 17: 1HNMR spectrum of compound 1 in CDCl3. 
 
 
Spectrum 18: 1HNMR spectrum of compound 2 in CDCl3. 





Spectrum 19: 1HNMR spectrum of compound 3 in CD3OD. 
 
 
Spectrum 20: 1HNMR spectrum of compound 4a in CDCl3. 
 
 
Spectrum 21: 1HNMR spectrum of compound 4b in CDCl3. 
 





Spectrum 22: 1HNMR spectrum of compound 5 in CD3OD. 
 
 
Spectrum 23: 1HNMR spectrum of compound 6b in CD3OD. 
 
 
Spectrum 24: 1HNMR spectrum of mixture containing compounds 7, 7.1 and 7.2 in CD3OD. 
 





Spectrum 25: 1HNMR spectrum of compound 8.1 in DMSO. 
 
 
Spectrum 26: 1HNMR spectrum of mixture containing compound 11 in CD3OD. 
 
 
Spectrum 27: 1HNMR spectrum of compound 12 in CDCl3. 
 





Spectrum 28: 1HNMR spectrum of compound 14 in DMSO.  
 
5.2.2 2-dimensional 1HNMR 
 
Spectrum 29: COSY 1HNMR of compound 8.1 in DMSO. 





Spectrum 30: ROESY 1HNMR spectrum of compound 8.1 in DMSO. 
 
Spectrum 31: ROESY 1HNMR spectrum of compound 14 in DMSO. 
 




5.2.3 13CNMR Spectra 
 
Spectrum 32: 13CNMR spectrum of compound 1 in CDCl3. 
 
 
Spectrum 33: 13CNMR spectrum of compound 3 in CD3OD. 
 
 
Spectrum 34: 13CNMR spectrum of compound 4a in CD3OD. 






Spectrum 35: 13CNMR spectrum of compound 5 in CD3OD. 
 
 
Spectrum 36: 13CNMR spectrum of compound 6b in CD3OD. 
 
 
Spectrum 37: 13CNMR spectrum of mixture containing compounds 7, 7.1, and 7.2 in CD3OD. 






Spectrum 38: 13CNMR spectrum of compound 8.1 in DMSO. 
 
 
Spectrum 39: 13CNMR spectrum of compound 12 in CDCl3. 





Spectrum 40: 13CNMR spectrum of compound 14 in DMSO. 
  




5.2.4 HPLC Traces 
 
 
Spectrum 41: HPLC trace for compound 1. 
 
Spectrum 42: HPLC trace for compound 3. 
 
Spectrum 43: HPLC trace of crude deesterification reaction mixture after 9h. The desired product, 
compound 4a, can be seen eluting at 18.2 minutes. Analysis was performed using a gradient of 10-100% 
MeOH over 15 minutes. 














































Spectrum 44: HPLC trace of crude deesterification reaction mixture after 21h. Compound 4a can be seen 




Spectrum 45: HPLC trace for compound 4b. 
 
Spectrum 46: HPLC trace for compound 5. Analysis was performed using a gradient of 10-100% MeOH 
over 15 minutes. 

























































Spectrum 47: HPLC trace of compound 6b. 
 
Spectrum 48: HPLC trace of mixture containing compounds 7, 7.1, and 7.2.  
 
Spectrum 49: HPLC trace of compound 8.1. 
  




5.2.5 HRMS Spectra 
 
Spectrum 50: HRMS spectrum of sample containing compounds 7, 7.1, and 7.2. 
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